↑ 疾患リストへ ← 戻る

 85. 特発性間質性肺炎 [臨床試験数:257,薬物数:256(DrugBank:93),標的遺伝子数:76,標的パスウェイ数:182] 

Searched query = "Idiopathic interstitial pneumonia", "Idiopathic pulmonary fibrosis", "Usual interstitial pneumonia", "Non-specific interstitial pneumonia", "NSIP", "Organizing pneumonia", "Desquamative interstitial pneumonia", "Respiratory bronchiolitis - associated interstitial lung disease", "RB-ILD", "Lymphocytic interstitial pneumonia", "Acute interstitial pneumonia", "Diffuse alveolar damage"
The queries were searched in Public_title, Scientific_title, and Condition of the data. Export date: 11/21/2019, 11/20/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.

Search in Page    e.g. "Phase 3", "Not recruiting", "Japan"    Synonyms (DrugBank) were also searched for.
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03720483January 202015 July 2019Inhaled NAC in Treatment of IPFPilot Study to Evaluate Inhaled N-Acetylcysteine in Pulmonary FibrosisIdiopathic Pulmonary Fibrosis (IPF)Drug: N-acetyl cysteine then Placebo;Drug: Placebo then N-acetyl cysteineUniversity of Colorado, DenverNot recruiting40 Years75 YearsAll50Phase 1/Phase 2United States
2NCT03865927November 1, 201930 September 2019GKT137831 in IPF Patients With Idiopathic Pulmonary FibrosisA Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial of GKT137831 in Patients With Idiopathic Pulmonary FibrosisIdiopathic Pulmonary FibrosisOther: Placebo Oral Tablet;Drug: GKT137831University of Alabama at BirminghamNot recruiting40 Years85 YearsAll60Phase 2United States
3ChiCTR19000271212019-10-284 November 2019The efficacy and safety of immunosuppressant in the treatment of nonspecific interstitial pneumonia (NSIP): a prospective, single-center, open, parallel-controlled trialThe efficacy and safety of immunosuppressant in the treatment of nonspecific interstitial pneumonia (NSIP): a prospective, single-center, open, parallel-controlled trialnonspecific interstitial pneumonia (NSIP)Group-1:Mycophenolate mofetil dispersible tablets 2 g /d; Steroid 0.75 mg/kg/d;Group-2:Tacrolimus capsule, 3mg/d, Steroid 0.75 mg/kg/d;Group-3:Cyclophosphamide 1-2mg/kg/d, Steroid 0.75 mg/kg/d;Control group:Steroid from 0.75 mg/kg/d to 15 mg/d.;Peking Union Medical College HospitalRecruiting1875BothGroup-1:30;Group-2:30;Group-3:30;Control group:30;Phase 4China
4JPRN-jRCTs03119011928/10/20195 November 2019A phase II Study of CBDCA + ETP + Nintedanib for SCLC with IPFA Phase II Study of Carboplatin and Etoposide Plus Nintedanib for Unresectable Limited/Extensive Disease Small Cell Lung Cancer with Idiopathic Pulmonary Fibrosis - TORG1835 / NEXT-SHIPUnresectable limited or extensive disease small cell lung cancer with idiopathic pulmonary fibrosisThe patients receive carboplatin(area under the curve 5 mg/mL, intravenously, day 1), etoposide (<75 years old:100mg/m2:>=75years old:80mg/m2;intravenously,days 1-3), and nintedanib (150mg twice a day, orally). The patients receive combination chemotherapy every3 weeks for 4 cycles until disease progression or unacceptable toxicity occurs. After completion or discontinuation of carboplatin plus etoposide, the patients continue nintedanib until the discontinuation criteria are satisfied.Takashi OGURASatoshi IKEDA;Thoracic Oncology Research GroupRecruiting>= 20age oldNot applicableBoth33Phase 2none
5NCT04071769October 1, 20199 September 2019Genentech MRI StudyUsing Xenon MRI to Evaluate the Efficacy of Therapies for Idiopathic Pulmonary FibrosisIdiopathic Pulmonary FibrosisDrug: Hyperpolarized 129 Xenon Gas Comparing Idiopathic Pulmonary Fibrosis (IPF) TreatmentDuke UniversityNot recruiting18 YearsN/AAll20Phase 2United States
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6NCT04072315September 9, 201930 September 2019Phase 2a Evaluation of PLN-74809 on avß6 Receptor Occupancy Using PET Imaging in Participants With IPF/A Phase 2a Evaluation of PLN-74809 on avß6 Receptor Occupancy Using PET Imaging in Participants With IPFIdiopathic Pulmonary FibrosisDrug: PLN-74809;Drug: Placebo;Radiation: Knottin tracerPliant Therapeutics, Inc.Stanford UniversityRecruiting40 Years80 YearsAll18Phase 2United States
7JPRN-jRCTs03119008405/09/20197 October 2019TORG1936 / AMBITIOUS studyA phase II study of Atezolizumab for advanced / recurrent Non-Small Cell Lung Cancer with Idiopathic Interstitial Pneumonias - TORG1936 / AMBITIOUS studyAdvanced / recurrent Non-small cell lung cancer with idiopathic interstitial pneumoniaAtezolizumab 1200mg, every 3 weeksTerufumi KATOSatoshi IKEDARecruiting>= 20age oldNot applicableBoth38Phase 2none
8NCT03800017September 1, 201915 July 2019Skeletal Muscle Function in Interstitial Lung DiseaseInvestigating the Role of Skeletal Muscle Dysfunction on Dyspnea and Exercise Intolerance in Interstitial Lung DiseaseInterstitial Lung Disease;Idiopathic Pulmonary Fibrosis;Hypersensitivity Pneumonitis;Scleroderma;Nonspecific Interstitial PneumoniaBiological: HyperoxiaUniversity of British ColumbiaNot recruiting40 Years80 YearsAll40N/A
9NCT03939520September 201920 May 2019Management of Progressive Disease in Idiopathic Pulmonary FibrosisPragmatic Management of Progressive Disease in Idiopathic Pulmonary Fibrosis: a Randomized TrialProgressive Idiopathic Pulmonary FibrosisDrug: pirfenidone and nintedanib;Drug: pirfenidone or nintedanibHospices Civils de LyonNot recruiting50 Years80 YearsAll210Phase 4France
10NCT04030026August 8, 201929 July 2019A Study of Nalbuphine (Extended Release) ER in Idiopathic Pulmonary Fibrosis (IPF) for Treatment of CoughPhase 2, Double-blind, Randomized, Placebo-controlled, Two-Treatment, Two-Period Crossover Efficacy and Safety Study in Idiopathic Pulmonary Fibrosis (IPF) With Nalbuphine ER Tablets for the Treatment of CoughNalbuphine;Idiopathic Pulmonary Fibrosis;CoughDrug: Nalbuphine ER;Drug: Placebo oral tabletTrevi TherapeuticsParexelNot recruiting18 Years80 YearsAll56Phase 2United Kingdom
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
11NCT03562416July 5, 201922 July 2019Continuation of Nintedanib After Single Lung Transplantation in IPF SubjectsNintedanib Plus Usual Transplant Care Compared to Usual Transplant Care Alone After Single Lung Transplantation in Patients With Idiopathic Pulmonary Fibrosis: a Pilot Randomized Controlled TrialIdiopathic Pulmonary Fibrosis;Lung Transplant; ComplicationsDrug: Nintedanib;Drug: Placebo Oral TabletTemple UniversityBoehringer IngelheimRecruiting35 Years70 YearsAll20Phase 2United States
12NCT03955146June 27, 201928 October 2019Evaluation of Efficacy and Safety of Pamrevlumab in Patients With Idiopathic Pulmonary FibrosisA Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects With Idiopathic Pulmonary Fibrosis (IPF)Idiopathic Pulmonary FibrosisDrug: Pamrevlumab;Drug: PlaceboFibroGenRecruiting40 Years85 YearsAll565Phase 3United States
13NCT03981094May 6, 201926 August 2019A Study of the Pharmacokinetic Interaction Between Pirfenidone and BMS-986278 in Healthy ParticipantsAn Open Label Study to Assess the Pharmacokinetic Interaction Between Pirfenidone and BMS-986278 Following a Single Oral Dose Administration in Healthy ParticipantsIdiopathic Pulmonary Fibrosis (IPF)Drug: BMS-986278;Drug: PirfenidoneBristol-Myers SquibbRecruiting21 Years65 YearsAll22Phase 1United States
14NCT03949530April 16, 201927 May 2019A Study of Safety & Blood Levels of IDL-2965 in Healthy Subjects and Patients With a Special Type of Pulmonary FibrosisIDL-2965 - A Phase I, Randomized, Double-blind, Placebo-controlled, Single and Multiple Oral Dose, Safety, Tolerability, and Pharmacokinetic Study in Healthy Subjects and Subjects With Idiopathic Pulmonary Fibrosis (IPF)Healthy Volunteers;Idiopathic Pulmonary FibrosisDrug: IDL-2965 Oral Capsule;Drug: PlacebosIndalo Therapeutics, Inc.Recruiting18 Years60 YearsAll120Phase 1United Kingdom
15NCT03864328March 29, 201911 November 2019A Phase 2b Study of Inhaled RVT-1601 for the Treatment of Persistent Cough in IPFRandomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study With Inhaled RVT-1601 for the Treatment of Persistent Cough in Patients With Idiopathic Pulmonary Fibrosis (IPF): SCENIC TrialPersistent Cough in IPF;Chronic Cough;IPFDrug: RVT-1601;Drug: PlaceboRespivant Sciences GmbHRespivant Sciences Inc.Recruiting40 Years89 YearsAll180Phase 2United States;Australia;Belgium;Canada;Czechia;Germany;Italy;Netherlands;New Zealand;Turkey;United Kingdom
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
16NCT03710824February 28, 201928 October 2019Investigating Trends in Quality of Life in Patients With Idiopathic Pulmonary Fibrosis (IPF) Under Treatment With NintedanibInvestigating Trends in Quality of Life in Patients With Idiopathic Pulmonary Fibrosis (IPF) Under Treatment With NintedanibIdiopathic Pulmonary FibrosisDrug: NintedanibBoehringer IngelheimRecruiting40 YearsN/AAll120Phase 2Greece
17NCT03650075February 25, 201915 July 2019To Determine Safety and Tolerability of MG-S-2525 and to Evaluate Its PK Profile in Healthy VolunteersA Phase I Study to Determine Safety and Tolerability of MG-S-2525 and to Evaluate Its Pharmacokinetic Profile in Healthy VolunteersIdiopathic Pulmonary Fibrosis (IPF)Drug: MG-S-2525Metagone Biotech Inc.Recruiting20 YearsN/AAll72Phase 1Taiwan
18NCT03832946February 19, 20194 March 2019A Study to Test the Efficacy and Safety of Inhaled TD139 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)GALACTIC-1 A Randomized, Double-blind, Multicentre, Parallel, Placebo-controlled Phase 2b Study in Subjects With Idiopathic Pulmonary Fibrosis Investigating the Efficacy and Safety of TD139, an Inhaled Galectin-3 Inhibitor Administered Via Dry Powder Inhaler Over 52 WeeksIdiopathic Pulmonary Fibrosis (IPF)Drug: TD139;Drug: PlaceboGalecto Biotech ABSyneos HealthRecruiting40 YearsN/AAll450Phase 2United States
19NCT03830125February 13, 20194 November 2019Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BBT-877 in Healthy SubjectsA Phase 1, 2-Stage, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BBT-877 Following Single and Multiple Ascending Doses in Healthy Adult SubjectsIdiopathic Pulmonary FibrosisDrug: BBT-877, Single dose;Drug: Placebo group;Drug: BBT-877, Multiple dosesBridge Biotherapeutics, Inc.KCRN Research, LLCRecruiting19 Years55 YearsAll64Phase 1United States
20EUCTR2018-001406-29-FR28/01/201928 February 2019A clinical study to test how effective and safe GLPG1690 is for subjects with idiopathic pulmonary fibrosis (IPF) when used together with standard medical treatmentA Phase 3, randomized, double-blind, parallel-group, placebo-controlled, multi-center study to evaluate the efficacy and safety of two doses of GLPG1690 in addition to local standard of care for minimum 52 weeks in subjects with idiopathic pulmonary fibrosis.Idiopatic pulmonary fibrosis
MedDRA version: 20.0 Level: SOC Classification code 10038738 Term: Respiratory, thoracic and mediastinal disorders System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders ;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
Product Name: GLPG1690
Product Code: G451990
Pharmaceutical Form: Film-coated tablet
INN or Proposed INN: Not applicable
Current Sponsor code: G451990
Other descriptive name: GLPG1690
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 200-
Pharmaceutical form of the placebo: Film-coated tablet
Route of administration of the placebo: Oral use
Product Name: GLPG1690
Product Code: G451990
Pharmaceutical Form: Film-coated tablet
INN or Proposed INN: Not applicable
Current Sponsor code: G451990
Other descriptive name: GLPG1690
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 100-
Pharmaceutical form of the placebo: Film-coated tablet
Route of administration of the placebo: Oral use
Galapagos NVAuthorised Female: yes
Male: yes
750Phase 3United States;Israel;Italy;France;Hungary;Mexico;Canada;Argentina;Poland;Brazil;South Africa;Germany;Netherlands;New Zealand;Korea, Republic of
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
21NCT03958071December 19, 201811 June 2019A Study Based on Medical Records That Looks at the Characteristics of Idiopathic Pulmonary Fibrosis Patients Grouped by the Type of Medication They Are TakingCharacteristics of IPF Patients Initiating Nintedanib, Pirfenidone or no Antifibrotic Treatment in the USIdiopathic Pulmonary FibrosisDrug: Nintedanib;Drug: Pirfenidone;Other: Untreated CohortBoehringer IngelheimNot recruiting40 YearsN/AAll13264N/AUnited States
22EUCTR2018-001405-87-ES12/12/201828 February 2019A clinical study to test how effective and safe GLPG1690 is for subjects with idiopathic pulmonary fibrosis (IPF) when used together with standard medical treatmentA Phase 3, randomized, double-blind, parallel-group, placebo-controlled, multi-center study to evaluate the efficacy and safety of two doses of GLPG1690 in addition to local standard of care for minimum 52 weeks in subjects with idiopathic pulmonary fibrosis.Idiopatic pulmonary fibrosis
MedDRA version: 20.0 Level: SOC Classification code 10038738 Term: Respiratory, thoracic and mediastinal disorders System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders ;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
Product Name: GLPG1690
Product Code: G451990
Pharmaceutical Form: Film-coated tablet
INN or Proposed INN: Not applicable
Current Sponsor code: G451990
Other descriptive name: GLPG1690
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 200-
Pharmaceutical form of the placebo: Film-coated tablet
Route of administration of the placebo: Oral use
Product Name: GLPG1690
Product Code: G451990
Pharmaceutical Form: Film-coated tablet
INN or Proposed INN: Not applicable
Current Sponsor code: G451990
Other descriptive name: GLPG1690
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 100-
Pharmaceutical form of the placebo: Film-coated tablet
Route of administration of the placebo: Oral use
Galapagos NVAuthorised Female: yes
Male: yes
750Phase 3United States;Taiwan;Greece;Finland;Spain;Turkey;Chile;United Kingdom;Czech Republic;Belgium;Peru;Australia;Denmark;Germany
23NCT03711162November 28, 201811 November 2019A Clinical Study to Test How Effective and Safe GLPG1690 is for Subjects With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of CareA Phase 3, Randomized, Double-blind, Parallel-group, Placebo-controlled Multicenter Study to Evaluate the Efficacy and Safety of Two Doses of GLPG1690 in Addition to Local Standard of Care for Minimum 52 Weeks in Subjects With Idiopathic Pulmonary FibrosisIdiopathic Pulmonary FibrosisDrug: GLPG1690;Drug: PlaceboGalapagos NVRecruiting40 YearsN/AAll750Phase 3United States;Australia;Belgium;Chile;Czechia;Denmark;Germany;Greece;Peru;Spain;Taiwan;Turkey;United Kingdom
24NCT03727802November 28, 201811 November 2019Safety, Tolerability, and Pharmacokinetic Study of TRK-250 for Patients With Idiopathic Pulmonary FibrosisTRK-250 - A Phase I, Double-Blind, Placebo-Controlled, Single and Multiple Inhaled Dose, Safety, Tolerability, and Pharmacokinetic Study of TRK-250 in Subjects With Idiopathic Pulmonary FibrosisIdiopathic Pulmonary FibrosisDrug: TRK-250;Drug: PlaceboToray Industries, IncRecruiting40 Years80 YearsAll34Phase 1United States
25NCT03717012November 15, 201828 October 2019Study of Pulmonary Rehabilitation in Patients With Idiopathic Pulmonary Fibrosis (IPF)Study of Pulmonary Rehabilitation In Nintedanib Treated Patients With IPF: Improvements in Activity, Exercise Endurance Time, and QoLIdiopathic Pulmonary FibrosisDrug: Nintedanib;Other: Pulmonary rehabilitation programBoehringer IngelheimRecruiting40 YearsN/AAll290Phase 4United States
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
26EUCTR2018-002632-24-FR13/11/201830 April 2019to evaluate a triple therapy: plasma exchange, rituximab, intravenous immunoglobulin (IVIg) and corticosteroid administration compared to standard corticosteroid therapy in patients for severe acute exacerbation of idiopathic pulmonaryTherapeutic plasma exchange, rituximab and intravenous immunoglobulins (IVIg) for severe acute exacerbation of idiopathic pulmonary fibrosis admitted in ICU: an open, randomized, controlled trial - EXCHANGE-IFPsevere acute exacerbation of idiopathic pulmonary fibrosis;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]Trade Name: RIXATHON 500 mg
Pharmaceutical Form: Concentrate for solution for infusion
Trade Name: PRIVIGEN 100mg/ml
Pharmaceutical Form: Solution for infusion
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)Authorised Female: yes
Male: yes
40Phase 3France
27NCT03733444November 5, 201822 October 2019A Clinical Study to Test How Effective and Safe GLPG1690 is for Subjects With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of CareA Phase 3, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multi-center Study to Evaluate the Efficacy and Safety of Two Doses of GLPG1690 in Addition to Local Standard of Care for Minimum 52 Weeks in Subjects With Idiopathic Pulmonary FibrosisIdiopathic Pulmonary FibrosisDrug: GLPG1690;Drug: PlaceboGalapagos NVRecruiting40 YearsN/AAll750Phase 3United States;Argentina;Canada;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;South Africa
28NCT03725852September 27, 201814 October 2019A Clinical Study to Test How Effective and Safe GLPG1205 is for Patients With Idiopathic Pulmonary Fibrosis (IPF)A Phase II Randomized, Double-blind, Placebo-controlled, 26-week Study to Evaluate the Efficacy, Safety and Tolerability of GLPG1205 in Subjects With Idiopathic Pulmonary FibrosisIdiopathic Pulmonary FibrosisDrug: GLPG1205;Drug: PlaceboGalapagos NVRecruiting40 YearsN/AAll60Phase 2Bulgaria;Croatia;Finland;France;Oman;Slovakia;Sweden;Ukraine
29NCT03573505September 24, 201830 September 2019An Efficacy and Safety Study of BG00011 in Participants With Idiopathic Pulmonary FibrosisA Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BG00011 in Patients With Idiopathic Pulmonary FibrosisIdiopathic Pulmonary FibrosisDrug: BG00011;Drug: PlaceboBiogenNot recruiting40 YearsN/AAll109Phase 2United States;Argentina;Australia;Belgium;Chile;Czechia;Denmark;France;Greece;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;United Kingdom
30EUCTR2017-003158-18-GR21/09/201815 October 2018Evaluating the Efficacy and Safety of BG00011 in Participants with Idiopathic Pulmonary FibrosisA Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BG00011 in Patients With Idiopathic Pulmonary Fibrosismild to moderate Idiopathic Pulmonary Fibrosis
MedDRA version: 20.0 Level: PT Classification code 10021240 Term: Idiopathic pulmonary fibrosis System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders ;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
Product Name: humanized anti-alpha v beta 6 mAb
Product Code: BG00011
Pharmaceutical Form: Solution for injection in pre-filled syringe
INN or Proposed INN: Not yet assigned
Current Sponsor code: BG00011
Other descriptive name: BG00011
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 56-
Pharmaceutical form of the placebo: Injection
Route of administration of the placebo: Subcutaneous use
Biogen Idec Research LimitedAuthorisedFemale: yes
Male: yes
290Phase 2United States;Greece;Spain;Turkey;Russian Federation;Israel;Italy;United Kingdom;France;Czech Republic;Canada;Argentina;Poland;Belgium;Australia;Denmark;Netherlands;Germany;Korea, Republic of
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
31NCT03286556September 4, 201830 September 2019Autoantibody Reduction for Acute Exacerbations of Idiopathic Pulmonary FibrosisStudy of Therapeutic Plasma Exchange, Rituximab and Intravenous Immunoglobulin for Acute Exacerbations of Idiopathic Pulmonary Fibrosis (STRIVE-IPF)Idiopathic Pulmonary Fibrosis, Acute Fatal FormDrug: Autoantibody Reductive Therapy;Drug: Treatment as Usual (TAU)University of Alabama at BirminghamNational Heart, Lung, and Blood Institute (NHLBI);Brigham and Women's Hospital;Temple University;University of PittsburghRecruiting40 Years85 YearsAll51Phase 2United States
32NCT03535545August 1, 201830 September 2019Preliminary Evaluation of [68Ga]CBP8 in Healthy Individuals, Lung Cancer, and Idiopathic Pulmonary Fibrosis PatientsPreliminary Evaluation of [68Ga]CBP8 in Healthy Individuals, Lung Cancer Patients Undergoing Radiation Therapy Prior to the Resection of Locally Advanced Tumors, and Idiopathic Pulmonary Fibrosis PatientsPulmonary Fibrosis;Lung CancerDrug: [68Ga]CBP8;Diagnostic Test: PET ImagingMassachusetts General HospitalNational Heart, Lung, and Blood Institute (NHLBI)Recruiting18 Years80 YearsAll25Phase 1United States
33EUCTR2017-003158-18-ES27/07/201820 August 2018Evaluating the Efficacy and Safety of BG00011 in Participants with Idiopathic Pulmonary FibrosisA Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BG00011 in Patients With Idiopathic Pulmonary Fibrosismild to moderate Idiopathic Pulmonary Fibrosis
MedDRA version: 20.0 Level: PT Classification code 10021240 Term: Idiopathic pulmonary fibrosis System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders ;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
Product Name: humanized anti-alpha v beta 6 mAb
Product Code: BG00011
Pharmaceutical Form: Solution for injection in pre-filled syringe
INN or Proposed INN: Not yet assigned
Current Sponsor code: BG00011
Other descriptive name: BG00011
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 56-
Pharmaceutical form of the placebo: Injection
Route of administration of the placebo: Subcutaneous use
Biogen Idec Research LimitedAuthorisedFemale: yes
Male: yes
290Phase 2United States;Greece;Spain;Turkey;Russian Federation;Israel;Italy;United Kingdom;France;Czech Republic;Canada;Argentina;Poland;Belgium;Australia;Denmark;Netherlands;Germany;Korea, Republic of
34NCT03619616July 16, 20184 November 2019Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single Ascending Dose of ZSP1603 in Healthy AdultsA Phase 1 Randomized,Double-Blind,Parallel-Group, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ZSP1603 in Chinese Healthy SubjectsIdiopathic Pulmonary Fibrosis(IPF);Solid TumorDrug: ZSP1603 7.5 mg;Drug: ZSP1603 12.5 mg;Drug: Placebo 12.5mg;Drug: ZSP1603 25 mg;Drug: Placebo 25mg;Drug: ZSP1603 50 mg;Drug: Placebo 50mgGuangdong Zhongsheng Pharmaceutical Co., Ltd.Not recruiting18 Years50 YearsAll40Phase 1China
35NCT03928847July 1, 20186 May 2019Fibroblast Specific Inhibition of LOXL2 and TGFbeta1 Signaling in Patients With Pulmonary Fibrosis.Fibroblast Specific Inhibition of LOXL2 and TGFbeta1 Signaling in Patients With Pulmonary Fibrosis.Idiopathic Pulmonary FibrosisDrug: Epigallocatechin-3-gallate (EGCG)University of California, San FranciscoNational Heart, Lung, and Blood Institute (NHLBI)Recruiting40 Years70 YearsAll35Phase 1/Phase 2United States
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
36EUCTR2017-004302-18-SK18/06/201828 February 2019A clinical study to test how effective and safe GLPG1205 is for patients with Idiopathic Pulmonary Fibrosis (IPF)A Phase II randomized, double-blind, placebo-controlled, 26-week study to evaluate the efficacy, safety and tolerability of GLPG1205 in subjects with idiopathic pulmonary fibrosis.Idiopathic pulmonary fibrosis
MedDRA version: 20.0 Level: PT Classification code 10021240 Term: Idiopathic pulmonary fibrosis System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders ;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
Product Name: GLPG1205
Product Code: G321605
Pharmaceutical Form: Capsule, hard
INN or Proposed INN: NA
CAS Number: 1445847-37-9
Current Sponsor code: G321605
Other descriptive name: GLPG1205
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 50-
Pharmaceutical form of the placebo: Capsule, hard
Route of administration of the placebo: Oral use
Galapagos NVAuthorised Female: yes
Male: yes
60Phase 2France;Egypt;Slovakia;Finland;Oman;Ukraine;Romania;Croatia;Bulgaria;Sweden
37NCT03538301June 18, 20184 November 2019A Phase 2 Study to Evaluate the Safety, Biological Activity, and PK of ND-L02-s0201 in Subjects With IPFA Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Biological Activity, and PK of ND-L02-s0201 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)Idiopathic Pulmonary FibrosisDrug: ND-L02-s0201;Other: Other: PlaceboNitto Denko CorporationRecruiting40 Years80 YearsAll120Phase 2United States;Germany;United Kingdom
38EUCTR2017-002667-17-FR06/06/201828 February 2019Study of pharmacodynamics, pharmacokinetics, safety and tolerability of VAY736 in patients with idiopathic pulmonary fibrosisA subject-, investigator-, and sponsor-blinded, randomized, placebo-controlled, multicenter study to investigate efficacy, safety, and tolerability of VAY736 in patients with idiopathic pulmonary fibrosisIdiopathic pulmonary fibrosis
MedDRA version: 20.0 Level: PT Classification code 10021240 Term: Idiopathic pulmonary fibrosis System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders ;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
Product Code: VAY736
Pharmaceutical Form: Powder for solution for injection/infusion
INN or Proposed INN: not established
Other descriptive name: VAY736
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 150-
Pharmaceutical form of the placebo: Solution for injection/infusion
Route of administration of the placebo: Subcutaneous use
Novartis Pharma AGAuthorised Female: yes
Male: yes
84Phase 2United States;France;Canada;Ireland;Germany;Italy;United Kingdom
39NCT03688334June 1, 20189 October 2018Acute Effects of Oxygen Supplementation Among IPF PatientsAcute Effects of Oxygen Supplementation During Exercise Among Patients With Idiopathic Pulmonary Fibrosis Without Resting HypoxemiaIdiopathic Pulmonary FibrosisDrug: Oxygen 40 %;Drug: Medical air (sham O2)George Papanicolaou HospitalRecruiting18 Years80 YearsAll15N/AGreece
40EUCTR2016-003827-45-GR29/05/20185 June 2018AN OPEN LABEL PHASE IV, MULTICENTER, INTERNATIONAL, INTERVENTIONAL STUDY TO EVALUATE THE EFFECT OF DIET ON GASTROINTESTINAL ADVERSE EVENTS IN PATIENTS WITH IPF TREATED WITH PIRFENIDONEAN OPEN LABEL PHASE IV, MULTICENTER, INTERNATIONAL, INTERVENTIONAL STUDY TO EVALUATE THE EFFECT OF DIET ON GASTROINTESTINAL ADVERSE EVENTS IN PATIENTS WITH IPF TREATED WITH PIRFENIDONE - MADIETIdiopathic Pulmonary Fibrosis
MedDRA version: 20.0 Level: PT Classification code 10021240 Term: Idiopathic pulmonary fibrosis System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders ;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
Trade Name: ESBRIET
Product Name: ESBRIET
Pharmaceutical Form: Capsule, hard
INN or Proposed INN: PIRFENIDONE
CAS Number: 53179-13-8
Current Sponsor code: ESBRIET
Other descriptive name: ESBRIET
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 801-
Trade Name: ESBRIET
Product Name: ESBRIET
Pharmaceutical Form: Capsule, hard
INN or Proposed INN: PIRFENIDONE
CAS Number: 53179-13-8
Current Sponsor code: ESBRIET
Other descriptive name: ESBRIET
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 1602-
Trade Name: ESBRIET
Product Name: ESBRIET
Pharmaceutical Form: Capsule, hard
INN or Proposed INN: PIRFENIDONE
CAS Number: 53179-13-8
Current Sponsor code: ESBRIET
Other descriptive name: ESBRIET
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 2403-
CIBERES - Instituto Carlos IIIInstitut d'Investigació Biomédica de Bellvitge (IDIBELL)AuthorisedFemale: yes
Male: yes
90Phase 4Greece;Spain
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
41NCT03502902May 22, 201817 September 2018The Safety, Tolerability and Pharmacokinetic Study of HEC68498 in Healthy Male and Female SubjectsHEC68498 - A Phase I, Double-blind, Placebo-controlled, Single Oral Dose, Safety, Tolerability, and Pharmacokinetic Study, Incorporating an Evaluation of the Effect of Food on the Pharmacokinetics of HEC68498 in Healthy Male and Female SubjectsIdiopathic Pulmonary FibrosisDrug: HEC 68498;Drug: PlaceboSunshine Lake Pharma Co., Ltd.CovanceRecruiting18 Years60 YearsAll72Phase 1United States
42NCT03500731April 19, 201815 April 2019Lung and Bone Marrow Transplantation for Lung and Bone Marrow FailureLung Transplant in Tandem With Bone Marrow Transplant for Combined Lung and Bone Marrow FailureIdiopathic Pulmonary Fibrosis;Emphysema or COPDBiological: CD3/CD19 negative hematopoietic stem cells;Drug: Rituximab;Drug: Alemtuzumab;Drug: Fludarabine;Drug: Thiotepa;Drug: G-CSF;Drug: HydroxyureaPaul SzabolcsRecruiting18 Years60 YearsAll8Phase 1/Phase 2United States
43NCT03422068March 16, 20184 November 2019This Study Tests Different Doses of BI 1015550 in Patients With Idiopathic Pulmonary Fibrosis (IPF). The Study Tests How BI 1015550 is Taken up by the Body and How Well it is Tolerated.Safety, Tolerability, and Pharmacokinetics of Multiple Rising Oral Doses of BI 1015550 in Patients With Idiopathic Pulmonary Fibrosis (IPF) on no Background Anti-fibrotic Therapy.Idiopathic Pulmonary FibrosisDrug: BI 1015550;Drug: PlaceboBoehringer IngelheimNot recruiting40 YearsN/AAll15Phase 1Belgium;Denmark;Finland;Germany;Italy;Netherlands;Spain;United Kingdom;France
44NCT02871401January 3, 201818 March 2019A Pilot Trial of Herpesvirus Treatment in Idiopathic Pulmonary Fibrosis (IPF)A Phase One-B (1B) Pilot Trial of Herpesvirus Treatment in Idiopathic Pulmonary Fibrosis (IPF)Idiopathic Pulmonary FibrosisDrug: Valganciclovir;Drug: PlaceboVanderbilt University Medical CenterGenentech, Inc.Not recruiting21 Years80 YearsAll30Phase 1United States
45NCT03287414December 20, 20179 September 2019Study of Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of VAY736 in Patients With Idiopathic Pulmonary FibrosisA Subject-, Investigator-, and Sponsor-blinded, Randomized, Placebo-controlled, Multicenter Study to Investigate Efficacy, Safety, and Tolerability of VAY736 in Patients With Idiopathic Pulmonary FibrosisIdiopathic Pulmonary FibrosisDrug: VAY736;Drug: PlaceboNovartis PharmaceuticalsRecruiting40 Years80 YearsAll84Phase 2United States;Canada;France;Germany;Ireland;Italy;United Kingdom
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
46NCT03183570November 8, 201715 July 2019Detection of Integrin avb6 in Idiopathic Pulmonary Fibrosis Using PET/CTDetection of Integrin avb6 in Idiopathic Pulmonary Fibrosis With [18F]FP-R01-MG-F2 PET/CTIdiopathic Pulmonary FibrosisDrug: [18F]FP-R01-MG-F2Stanford UniversityPliant Therapeutics, Inc.Recruiting60 YearsN/AAll10Early Phase 1United States
47NCT03281200October 24, 201718 June 2018Chart Review Study to Describe the Clinical Profile of Idiopathic Pulmonary Fibrosis (IPF) Patients Treated With Nintedanib (OFEV®) in Real-world Practice in SpainA Multicentre, Retrospective Chart Review Study to Describe the Clinical Profile of Idiopathic Pulmonary Fibrosis (IPF) Patients Treated With Nintedanib (OFEV®) in Real-world Practice in Spain.Idiopathic Pulmonary FibrosisDrug: L01XE31 - Nintedanib;Drug: L01XE - Protein kinase inhibitors;Drug: L01X - Other antineoplastic agents;Drug: L01 - Antineoplastic agents;Drug: L - Antineoplastic and immunomodulating agentsBoehringer IngelheimNot recruiting18 YearsN/AAll173Phase 1Spain
48NCT03208933October 23, 201722 October 2019Open-label Study to Assess the Effectiveness of Pirfenidone in Participants With Idiopathic Pulmonary Fibrosis (IPF).Local Open-label Multicenter Study to Assess the Effectiveness of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis in Russian Clinical PracticeIdiopathic Pulmonary FibrosisDrug: PirfenidoneHoffmann-La RocheNot recruiting40 Years80 YearsAll59Phase 3Russian Federation
49JPRN-UMIN0000294112017/10/152 April 2019Phase III study of perioperative pirfenidone therapy in patients with non-small-cell lung cancer combined with idiopathic pulmonary fibrosis (IPF) for confirming the effect for prevention of postoperative acute exacerbationnon-small-cell lung cancer combined with idiopathic pulmonary fibrosisOral pirfenidone (600mg) is administrated for 14days after registration, and oral pirfenidone (1200mg) for more 14days before surgery. It's recommended continuing oral pirfenidone as long as possible even after surgery.
Acute exacerbation prophylaxis is performed (not specified. but decided in each facility)
North East Japan Study GroupRecruiting20years-oldNot applicableMale and Female230Phase 3Japan
50JPRN-UMIN0000263762017/09/0110 September 2019Long-term Effect of Pulmonary Rehabilitation under Nintedanib treatment in Idiopathic Pulmonary FibrosisLong-term Effect of Pulmonary Rehabilitation under Nintedanib treatment in Idiopathic Pulmonary Fibrosis - Long-term Effect of Pulmonary Rehabilitation under Nintedanib treatment in IPFIdiopathic pulmonary fibrosis(IPF)Short-term induction pulmonary rehabilitation (2/1w for the first 12w) + Maintenance pulmonary rehabilitation and outpatient visit (1/4w) Total 52w. / No intervention
Nintedanib / both group
Central Japan Lung Study GrouRecruiting40years-old80years-oldMale and Female84Phase 4Japan
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
51NCT03142191July 26, 201722 October 2019A Study to Evaluate the Efficacy and Safety of CC-90001 in Subjects With Idiopathic Pulmonary FibrosisA Phase 2, 24-Week, Randomized, Double-blind, Placebo-controlled, Multicenter Study, With an 80-Week Active Treatment Extension, to Evaluate the Efficacy and Safety of CC-90001 in Subjects With Idiopathic Pulmonary FibrosisIdiopathic Pulmonary Fibrosis;Fibrosis;Idiopathic Interstitial Pneumonias;Pathologic Processes;Lung Diseases, Interstitial;Lung Diseases;Respiratory Tract DiseasesDrug: CC-90001;Other: PlaceboCelgeneRecruiting40 YearsN/AAll210Phase 2United States;Australia;Brazil;Canada;Colombia;Germany;Greece;Romania;Russian Federation;Taiwan;Turkey;Ukraine;United Kingdom;China
52NCT03069989June 13, 201721 January 2019Single Doses of GSK3008348 in Idiopathic Pulmonary Fibrosis (IPF) Participants Using Positron Emission Tomography (PET) ImagingA Study of Single Doses to Evaluate the Safety, Tolerability, Pharmacokinetics and Target Engagement of Nebulised GSK3008348 in Idiopathic Pulmonary Fibrosis Patients, Using Positron Emission Tomography (PET) ImagingIdiopathic Pulmonary FibrosisDrug: [18F]-FBA-A20FMDV2;Drug: Placebo;Drug: GSK3008348GlaxoSmithKlineNot recruiting50 YearsN/AAll8Phase 1United Kingdom
53JPRN-jRCTs07118004923/05/201710 September 2019Japanese Intergroup Study of Nintedanib for NSCLC with IPFA randomized phase III study of carboplatin plus nab-paclitaxel with or without nintedanib for advanced non-small-cell lung cancer with idiopathic pulmonary fibrosis - J-SONICAdvanced Non-small cell lung cancer with idiopathic pulmonary fibrosiscarboplatin + nab-paclitaxel
carboplatin + nab-paclitaxel + nintedanib
Isamu OkamotoKohei OtsuboRecruiting>= 20age oldNot applicableBoth240Phase 3none
54NCT03092102May 20, 201717 September 2018The Safety, Tolerability and Pharmacokinetic Study of HEC585 in Healthy Male and Female SubjectsA Phase I, Double-blind, Placebo-controlled, Single and Multiple Oral Dose, Safety, Tolerability and Pharmacokinetic Study of HEC585 in Healthy Male and Female SubjectsIdiopathic Pulmonary FibrosisDrug: HEC585Sunshine Lake Pharma Co., Ltd.Recruiting18 Years60 YearsAll84Phase 1United States
55JPRN-UMIN0000267992017/05/127 October 2019A randomized phse 3 study of carboplatin plus nab-paclitaxel with or without nintedanib for advanced non-small-cell lung cancer with idiopathic pulmonary fibrosisA randomized phse 3 study of carboplatin plus nab-paclitaxel with or without nintedanib for advanced non-small-cell lung cancer with idiopathic pulmonary fibrosis - Japanese Intergroup Study of Nintedanib for NSCLC with IPF (J-SONIC)Non-small-cell lung cancer with idiopathic pulmonary fibrosisA: 4 cycles of Carboplatin (AUC 6, day 1) plus nab-Paclitaxel (100 mg/m2, day 1, 8, 15) repeated every 3 weeks
B: 4 cycles of Carboplatin (AUC 6, day 1) plus nab-Paclitaxel (100 mg/m2, day 1, 8, 15) in combination with nintedanib (150 mg B.I.D, daily) repeated every 3 weeks followed by single-agent administration of nintedanib (150 mg B.I.D, daily)
Research Institute for Diseases of the Chest, Kyushu UniversityRecruiting20years-oldNot applicableMale and Female240Phase 3Japan
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
56EUCTR2016-003473-17-GR05/05/201719 November 2018Investigation to Efficacy and Safety of CC-90001 in patients with Idiopathic Pulmonary FibrosisA Phase 2, 24-Week Randomized, Double-blind, Placebo-Controlled Multicenter Study, With an 80-Week Active Treatment Extension, to Evaluate the Efficacy and Safety of CC-90001 in Subjects with Idiopathic Pulmonary FibrosisIDIOPATHIC PULMONARY FIBROSIS
MedDRA version: 20.0 Level: LLT Classification code 10067761 Term: Exacerbation of idiopathic pulmonary fibrosis System Organ Class: 100000004855 ;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
Product Code: CC-90001
Pharmaceutical Form: Film-coated tablet
CAS Number: 1403859-14-2
Current Sponsor code: CC-90001
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 200-
Pharmaceutical form of the placebo: Film-coated tablet
Route of administration of the placebo: Oral use
Celgene CorporationAuthorisedFemale: yes
Male: yes
135Phase 2United States;Taiwan;Greece;Turkey;Russian Federation;Colombia;United Kingdom;France;Canada;Brazil;Romania;Australia;Germany
57NCT03115619April 18, 201722 October 2019Quality of Life Study in Participants With IPF Under Pirfenidone TreatmentA Multicenter, Post-Marketing, Non-Interventional, Observational Study to Evaluate Quality of Life in Patients in Greece With Idiopathic Pulmonary Fibrosis Under Treatment With Pirfenidone - The Pneumon StudyIdiopathic Pulmonary FibrosisDrug: PirfenidoneHoffmann-La RocheNot recruiting18 YearsN/AAll102Phase 3Greece
58NCT02759120March 22, 201730 September 2019CleanUP IPF for the Pulmonary Trials CooperativeStudy of Clinical Efficacy of Antimicrobial Therapy Strategy Using Pragmatic Design in Idiopathic Pulmonary FibrosisIdiopathic Pulmonary FibrosisDrug: Antimicrobial therapy: Co-trimoxazole or Doxycycline;Other: No Intervention: Standard of CareWeill Medical College of Cornell UniversityDuke Clinical Research Institute;University of Chicago;University of Washington;University of Pittsburgh;National Heart, Lung, and Blood Institute (NHLBI)Not recruiting40 YearsN/AAll509Phase 3United States
59NCT02951429January 13, 201714 October 2019Efficacy, Safety, and Tolerability Study of Pirfenidone in Combination With Sildenafil in Participants With Advanced Idiopathic Pulmonary Fibrosis (IPF) and Risk of Group 3 Pulmonary HypertensionA Phase IIb, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Sildenafil Added to Pirfenidone in Patients With Advanced Idiopathic Pulmonary Fibrosis and Risk of Group 3 Pulmonary HypertensionIdiopathic Pulmonary FibrosisDrug: Pirfenidone;Drug: Placebo;Drug: SildenafilHoffmann-La RocheNot recruiting40 Years80 YearsAll177Phase 2Belgium;Canada;Czechia;Egypt;Germany;Greece;Hungary;Israel;Italy;Netherlands;South Africa;Spain;Turkey;Czech Republic;United Arab Emirates
60NCT03018756January 20171 October 2018Nebulized Fentanyl in Patients With Mild to Moderate Idiopathic Pulmonary Fibrosis and Chronic DyspneaUse of Nebulized Fentanyl in Patients With Mild-to-Moderate Idiopathic Pulmonary Fibrosis and Chronic DyspneaIdiopathic Pulmonary FibrosisDrug: Fentanyl Citrate;Drug: PlaceboQueen's UniversityBoehringer Ingelheim (Canada) LTDRecruiting40 YearsN/AAll20Phase 3Canada
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
61NCT02874989December 16, 201615 July 2019Targeting Pro-Inflammatory Cells in Idiopathic Pulmonary Fibrosis: a Human TrialTargeted Removal of Pro-Inflammatory Cells: An Open Label Human Pilot Study in Idiopathic Pulmonary FibrosisIdiopathic Pulmonary Fibrosis (IPF)Drug: Dasatinib + Quercetin;Drug: PlaceboWake Forest University Health SciencesMayo Clinic;The University of Texas Health Science Center at San AntonioNot recruiting50 YearsN/AAll26Phase 1United States
62NCT02989168November 201616 December 2017Study to Evaluate the Effect of GBT440 Administered to Subjects With IPF on Supplemental Oxygen at RestA Phase II Open Label Study to Evaluate the Effect of GBT440 on Hypoxemia in Subjects With Idiopathic Pulmonary Fibrosis (IPF) Who Are Using Supplemental Oxygen at Rest (ZEPHYR)Idiopathic Pulmonary FibrosisDrug: GBT440Global Blood TherapeuticsNot recruiting45 Years85 YearsAll14Phase 2United States;United Kingdom
63NCT03050255November 201618 December 2018Short-term Effects of Supplemental Oxygen in Patients With IPFShort-term Effects of Supplemental Oxygen During Walking in Hypoxemic Patients With Idiopathic Pulmonary FibrosisIdiopathic Pulmonary Fibrosis (IPF)Other: Oxygen (4Liter/min);Other: Oxygen (2Liter/min);Other: Medical airKlinikum Berchtesgadener Land der Schön-KlinikenLinde AGNot recruitingN/AN/AAll53N/AGermany
64EUCTR2015-005131-40-ES20/10/201631 October 2016A Study to Evaluate the Efficacy, Safety, and Tolerability of Sildenafil Added to Pirfenidone in Patients with Advanced Idiopathic Pulmonary Fibrosis and Intermediate or High Probability of Pulmonary Hypertension due to the lung disease.A PHASE IIb, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF SILDENAFIL ADDED TO PIRFENIDONE IN PATIENTS WITH ADVANCED IDIOPATHIC PULMONARY FIBROSIS AND INTERMEDIATE OR HIGH PROBABILITY OF GROUP 3 PULMONARY HYPERTENSION.Pulmonary Hypertension in patients with Idiopathic pulmonary fibrosis (IPF)
MedDRA version: 19.0 Level: PT Classification code 10021240 Term: Idiopathic pulmonary fibrosis System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders ;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
Trade Name: Esbriet
Product Name: Esbriet
Product Code: RO0220912
Pharmaceutical Form: Capsule, hard
INN or Proposed INN: PIRFENIDONE
CAS Number: 53179-13-8
Current Sponsor code: RO0220912
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 267-
Trade Name: Sildenafil
Product Name: Sildenafil
Product Code: RO0280296
Pharmaceutical Form: Capsule, hard
INN or Proposed INN: SILDENAFIL
CAS Number: 139755-83-2
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 20-
Pharmaceutical form of the placebo: Capsule
Route of administration of the placebo: Oral use
F. Hoffmann-La Roche LtdAuthorisedFemale: yes
Male: yes
176Phase 2United Arab Emirates;Greece;Spain;Turkey;Israel;Italy;Egypt;Czech Republic;Hungary;Canada;Belgium;South Africa;Germany;Netherlands
65NCT02885961August 20165 September 2016The Coagulation Cascade in Idiopathic Pulmonary FibrosisInvestigating the Role of the Coagulation Cascade in Idiopathic Pulmonary FibrosisIdiopathic Pulmonary Fibrosis;IPF;Interstitial Lung DiseaseDrug: Dabigatran;Radiation: FDG PET scanUniversity College, LondonNot recruiting40 Years80 YearsBoth12N/A
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
66EUCTR2015-002619-14-DE21/07/20165 June 2018Efficacy and safety of nintedanib when co-administered with sildenafil in IPF patients with advanced lung function impairmentINSTAGE(TM): A 24-week, double-blind, randomized, parallel-group study evaluating the efficacy and safety of oral nintedanib coadministrated with oral sildenafil, compared to treatment with nintedanib alone, in patients with idiopathic pulmonary fibrosis (IPF) and advanced lung function impairment - INSTAGE(TM)patients with idiopathic pulmonary fibrosis (IPF) and advanced lung function impairment
MedDRA version: 19.0 Level: PT Classification code 10021240 Term: Idiopathic pulmonary fibrosis System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders ;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
Trade Name: Ofev
Product Name: Ofev 100 mg capsule
Product Code: nintedanib
Pharmaceutical Form: Capsule, soft
INN or Proposed INN: nintedanib
CAS Number: 656247-17-5
Other descriptive name: NINTEDANIB
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 100-
Trade Name: Ofev
Product Name: Ofev 150 mg capsule
Product Code: nintedanib
Pharmaceutical Form: Capsule, soft
INN or Proposed INN: nintedanib
CAS Number: 656247-17-5
Other descriptive name: NINTEDANIB
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 150-
Trade Name: Revatio
Product Name: Revatio 20 mg
Product Code: sildenafil
Pharmaceutical Form: Capsule, hard
INN or Proposed INN: SILDENAFIL
CAS Number: 139755-83-2
Other descriptive name: sildenafil
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 20-
Pharmaceutical form of the placebo: Capsule, hard
Route of administration of the placebo: Oral use
Boehringer Ingelheim Pharma GmbH & Co. KGNot RecruitingFemale: yes
Male: yes
300Phase 3United States;Spain;United Kingdom;Italy;India;France;Mexico;Canada;Belgium;Australia;Germany;China;Japan;Korea, Republic of
67NCT02802345June 30, 20163 December 2018Efficacy and Safety of Nintedanib When Co-administered With Sildenafil in Idiopathic Pulmonary Fibrosis Patients With Advanced Lung Function ImpairmentINSTAGE: A 24-week, Double-blind, Randomized, Parallel-group Study Evaluating the Efficacy and Safety of Oral Nintedanib Co-administered With Oral Sildenafil, Compared to Treatment With Nintedanib Alone, in Patients With Idiopathic Pulmonary Fibrosis (IPF) and Advanced Lung Function ImpairmentIdiopathic Pulmonary FibrosisDrug: Nintedanib;Drug: Placebo;Drug: SildenafilBoehringer IngelheimNot recruiting40 YearsN/AAll274Phase 3United States;Australia;Belgium;Canada;France;Germany;India;Italy;Japan;Korea, Republic of;Mexico;Spain;United Kingdom
68EUCTR2015-003148-38-ES13/06/201618 June 2018Effect of nintedanib on biomarkersA 12-week, double blind, randomised, placebo controlled, parallel group trial followed by a single active arm phase of 40 weeks evaluating the effect of oral nintedanib 150 mg twice daily on change in biomarkers of extracellular matrix (ECM) turnover in patients with idiopathic pulmonary fibrosis (IPF) and limited forced vital capacity (FVC) impairment.MedDRA version: 18.1 Level: PT Classification code 10021240 Term: Idiopathic pulmonary fibrosis System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders ;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]Trade Name: Ofev
Product Name: Ofev 100 mg capsule
Product Code: nintedanib
Pharmaceutical Form: Capsule, soft
INN or Proposed INN: nintedanib
CAS Number: 656247-17-5
Other descriptive name: NINTEDANIB
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 100-
Pharmaceutical form of the placebo: Capsule, soft
Route of administration of the placebo: Oral use
Trade Name: Ofev
Product Name: Ofev 150 mg capsule
Product Code: nintedanib
Pharmaceutical Form: Capsule, soft
INN or Proposed INN: nintedanib
CAS Number: 656247-17-5
Other descriptive name: NINTEDANIB
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 100-
Pharmaceutical form of the placebo: Capsule, soft
Route of administration of the placebo: Oral use
Boehringer Ingelheim España, S.A.Not RecruitingFemale: yes
Male: yes
490Phase 4United States;Finland;Spain;United Kingdom;France;Czech Republic;Hungary;Belgium;Poland;Australia;Germany;Japan;Korea, Republic of
69NCT02788474June 9, 20162 July 2018Effect of Nintedanib on Biomarkers of Extracellular Matrix Turnover in Patients With Idiopathic Pulmonary Fibrosis and Limited Forced Vital Capacity ImpairmentA 12-week, Double Blind, Randomised, Placebo Controlled, Parallel Group Trial Followed by a Single Active Arm Phase of 40 Weeks Evaluating the Effect of Oral Nintedanib 150 mg Twice Daily on Change in Biomarkers of Extracellular Matrix (ECM) Turnover in Patients With Idiopathic Pulmonary Fibrosis (IPF) and Limited Forced Vital Capacity (FVC) Impairment.Idiopathic Pulmonary FibrosisDrug: nintedanib;Drug: placeboBoehringer IngelheimNot recruiting40 YearsN/AAll347Phase 4United States;Australia;Belgium;Czechia;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Poland;Spain;United Kingdom;Czech Republic
70EUCTR2015-003148-38-GB06/06/201628 February 2019Effect of nintedanib on biomarkersA 12-week, double blind, randomised, placebo controlled, parallel group trial followed by a single active arm phase of 40 weeks evaluating the effect of oral nintedanib 150 mg twice daily on change in biomarkers of extracellular matrix (ECM) turnover in patients with idiopathic pulmonary fibrosis (IPF) and limited forced vital capacity (FVC) impairment. MedDRA version: 19.0 Level: PT Classification code 10021240 Term: Idiopathic pulmonary fibrosis System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders ;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]Trade Name: Ofev
Product Name: Ofev 100 mg capsule
Product Code: nintedanib
Pharmaceutical Form: Capsule, soft
INN or Proposed INN: nintedanib
CAS Number: 656247-17-5
Other descriptive name: NINTEDANIB
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 100-
Pharmaceutical form of the placebo: Capsule, soft
Route of administration of the placebo: Oral use
Trade Name: Ofev
Product Name: Ofev 150 mg capsule
Product Code: nintedanib
Pharmaceutical Form: Capsule, soft
INN or Proposed INN: nintedanib
CAS Number: 656247-17-5
Other descriptive name: NINTEDANIB
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 100-
Pharmaceutical form of the placebo: Capsule, soft
Route of administration of the placebo: Oral use
Boehringer Ingelheim LimitedNot Recruiting Female: yes
Male: yes
490Phase 4United States;Finland;Spain;United Kingdom;France;Czech Republic;Hungary;Belgium;Poland;Australia;Germany;Japan;Korea, Republic of
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
71NCT02688647June 201626 August 2019A Study to Evaluate the Safety, Tolerability, and Activity of KD025 in Subjects With Idiopathic Pulmonary FibrosisA Randomized, Phase 2, Open-Label, Multicenter Study to Evaluate the Safety, Tolerability, and Activity of KD025 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)Idiopathic Pulmonary FibrosisDrug: KD025;Drug: Standard of CareKadmon Corporation, LLCNot recruiting18 YearsN/AAll76Phase 2United States
72NCT02846324June 201616 December 2017Study to Evaluate the Safety and Tolerability of GBT440 Administered to Subjects With IPFA Phase II Randomized, Placebo-Controlled Study of GBT440 to Evaluate the Safety, Tolerability, Pharmacokinetics and Effect on Hypoxemia in Subjects With Idiopathic Pulmonary Fibrosis (IPF)Idiopathic Pulmonary FibrosisDrug: GBT440;Drug: PlaceboGlobal Blood TherapeuticsNot recruiting45 Years80 YearsAll39Phase 2United States
73JPRN-JapicCTI-16332601/5/201616 July 2019Phase III clinical study of ART-123 for the treatment of acute exacerbation of idiopathic pulmonary fibrosisPhase III clinical study of ART-123 for the treatment of acute exacerbation of idiopathic pulmonary fibrosisAcute exacerbation of idiopathic pulmonary fibrosis (AE-IPF)Intervention name : ART-123
INN of the intervention : thrombomodulin alfa
Dosage And administration of the intervention : 380 U/kg/day by intravenous drip infusion in addition to standard of care steroid therapy
Control intervention name : Placebo
Dosage And administration of the control intervention : Placebo by intravenous drip infusion in addition to standard of care steroid therapy
ASAHI KASEI PHARMA CORPORATIONRecruiting4085BOTHPhase 3
74NCT02739165May 201628 January 2019Clinical Study of ART-123 for the Treatment of Acute Exacerbation of Idiopathic Pulmonary FibrosisPhase III Clinical Study of ART-123 for the Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis: a Multicenter Randomized Placebo-controlled Double-blind Study to Assess the Efficacy and Safety of ART-123Idiopathic Pulmonary FibrosisDrug: ART-123;Drug: PlaceboAsahi Kasei Pharma CorporationNot recruiting40 Years85 YearsAll74Phase 3Japan
75NCT02606877April 19, 20168 January 2018A Study to Compare the Amount of Nintedanib and Pirfenidone in the Blood When Nintedanib and Pirfenidone Are Given Separately or in CombinationInvestigation of Drug-drug Interaction Between Nintedanib and Pirfenidone in Patients With IPF (an Open Label, Multiple-dose, Two Group Study)Idiopathic Pulmonary FibrosisDrug: nintedanib;Drug: pirfenidoneBoehringer IngelheimNot recruiting40 YearsN/AAll37Phase 4United Kingdom
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
76JPRN-UMIN0000215912016/04/047 October 2019The pilot study of Nintedanib and Carboplatin plus Paclitaxel for advanced non-small cell lung cancer with idiopathic interstitial pneumoniaThe pilot study of Nintedanib and Carboplatin plus Paclitaxel for advanced non-small cell lung cancer with idiopathic interstitial pneumonia - The pilot study of Nintedanib and Carboplatin plus Paclitaxel for advanced non-small cell lung cancer with idiopathic interstitial pneumoniaAdvanced non-small cell lung cancer with idiopathic interstitial pneumoniacarboplatin AUC6 D1
paclitaxel 200mg/m D1
tryweekly 4cycle
nintedanib 150mg twice daily
Hirosaki University Graduate School of MedicineRecruiting20years-oldNot applicableMale and Female30Not selectedJapan
77NCT02745184April 201624 September 2018Clinical Efficacy and Safety of Autologous Lung Stem Cell Transplantation in Patients With Idiopathic Pulmonary FibrosisIdiopathic Pulmonary FibrosisBiological: Lung stem cellsShanghai East HospitalRegend TherapeuticsRecruiting40 Years75 YearsAll20Phase 1/Phase 2China
78EUCTR2015-004157-41-GB21/03/201630 April 2019Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter, Exploratory Phase IIa Study to Assess Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of GLPG1690 Administered for 12 Weeks in Subjects with Idiopathic Pulmonary Fibrosis (IPF)Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter, Exploratory Phase IIa Study to Assess Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of GLPG1690 Administered for 12 Weeks in Subjects with Idiopathic Pulmonary Fibrosis (IPF)Idiopathic pulmonary fibrosis (IPF)
MedDRA version: 18.1 Level: PT Classification code 10021240 Term: Idiopathic pulmonary fibrosis System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders ;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
Product Name: GLPG1690
Product Code: G451990
Pharmaceutical Form: Capsule
Current Sponsor code: G451990
Other descriptive name: GLPG1690
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 200-
Pharmaceutical form of the placebo: Capsule
Route of administration of the placebo: Oral use
Galapagos NVNot Recruiting Female: yes
Male: yes
24Phase 2Ukraine;United Kingdom
79NCT02503657March 201611 June 2019Safety and Tolerability Study in Subjects With Idiopathic Pulmonary Fibrosis (IPF)A Randomized, Placebo-Controlled, Double-Blind Six Month Study Followed by an Open-Label Extension Phase to Evaluate the Efficacy, Safety and Tolerability of MN-001 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)Idiopathic Pulmonary Fibrosis;IPFDrug: tipelukast;Drug: PlaceboMediciNovaRecruiting21 Years80 YearsAll15Phase 2United States
80EUCTR2015-003280-11-DE25/02/20163 July 2017A Study of the Safety and Tolerability of Pirfenidone (Esbriet) in Combination with Nintedanib (Ofev) in Patients with Idiopathic Pulmonary FibrosisAN EXPLORATORY MULTICENTER, OPEN-LABEL, SINGLE ARM STUDY OF THE SAFETY AND TOLERABILITY OF PIRFENIDONE (ESBRIET®) IN COMBINATION WITH NINTEDANIB (OFEV®) IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSISIdiopathic Pulmonary Fibrosis (IPF)
MedDRA version: 19.0 Level: PT Classification code 10021240 Term: Idiopathic pulmonary fibrosis System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders ;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
Trade Name: Esbriet
Product Name: Esbriet
Product Code: RO0220912
Pharmaceutical Form: Capsule, hard
INN or Proposed INN: PIRFENIDONE
CAS Number: 53179-13-8
Current Sponsor code: RO0220912
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 267-
Trade Name: Ofev
Product Name: Ofev
Product Code: 534-1508
Pharmaceutical Form: Capsule, soft
INN or Proposed INN: NINTEDANIB
CAS Number: 656247-17-5
Current Sponsor code: 534-1508
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 100-
Trade Name: Ofev
Product Name: Ofev
Product Code: 534-1508
Pharmaceutical Form: Capsule, soft
INN or Proposed INN: NINTEDANIB
CAS Number: 656247-17-5
Current Sponsor code: 534-1508
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 150-
F. Hoffmann-La Roche LtdNot RecruitingFemale: yes
Male: yes
80Phase 4France;United States;Canada;Spain;Denmark;Netherlands;Germany;Italy
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
81EUCTR2014-005658-20-BG23/02/201630 April 2018FG-3019 treatment in Idiopathic Pulmonary Fibrosis (IPF) patients.A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of FG-3019 in Patients with Idiopathic Pulmonary FibrosisIdiopathic Pulmonary Fibrosis
MedDRA version: 19.1 Level: PT Classification code 10021240 Term: Idiopathic pulmonary fibrosis System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders
MedDRA version: 19.1 Level: SOC Classification code 10038738 Term: Respiratory, thoracic and mediastinal disorders System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders
MedDRA version: 19.1 Level: HLT Classification code 10033979 Term: Parenchymal lung disorders NEC System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders ;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
Product Name: FG-3019 10mg/mL in 10 mL vials
Product Code: FG-3019
Pharmaceutical Form: Solution for infusion
INN or Proposed INN: Pamrevlumab
CAS Number: 946415-13-0
Current Sponsor code: FG-3019
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 10-
Pharmaceutical form of the placebo: Solution for infusion
Route of administration of the placebo: Intravenous use
FibroGen, Inc.Not RecruitingFemale: yes
Male: yes
136Phase 2United States;Canada;Australia;South Africa;Bulgaria;New Zealand;India
82JPRN-UMIN0000207222016/01/262 April 2019Prospective study of efficiency of fibrosis score in computed tomography as predictor after treatment with Nintedanib for idiopathic pulmonary fibrosisidiopathic pulmonary fibrosisadministration of 150mg of nintedanib twice dailyKanagawa Cardiovascular and Respiratory CenterRecruiting40years-oldNot applicableMale and Female30Not applicableJapan
83JPRN-UMIN0000206822016/01/222 April 2019The comparison of the efficacy and safety of pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosisIdiopathic pulmonary fibrosispirfenidone 12 months 200-600mg t.i.d or b.i.d
nintedanib 12 months 100-150mg b.i.d
National Hospital Organization Ibarakihigashi National Hospital The center of Chest Diseases and Severe Motor&Intellectual DisabilitiesNot Recruiting20years-oldNot applicableMale and Female60Not applicableJapan
84NCT02648048January 15, 201616 December 2017A Study of Oral Vismodegib in Combination With Pirfenidone in Participants With Idiopathic Pulmonary FibrosisA Single Arm, Multicenter, Open-label, Phase 1b Study to Assess the Safety and Tolerability of Oral Vismodegib in Combination With Pirfenidone in Patients With Idiopathic Pulmonary FibrosisIdiopathic Pulmonary FibrosisDrug: Pirfenidone;Drug: VismodegibHoffmann-La RocheNot recruiting40 Years80 YearsAll21Phase 1United States;Germany
85NCT02612051December 4, 201516 December 2017First Time in Human (FTIH) Study of GSK3008348 in Healthy Volunteers and Idiopathic Pulmonary Fibrosis PatientsA FTIH Study With GSK3008348 in Healthy Volunteers and Patients With Idiopathic Pulmonary FibrosisIdiopathic Pulmonary FibrosisDrug: GSK3008348 Nebuliser solution;Drug: Placebo Nebuliser solution;Radiation: GSK26346763: ([18F]-FBA-A20FMDV2) IV infusionGlaxoSmithKlineNot recruiting18 YearsN/AAll40Phase 1United Kingdom
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
86EUCTR2014-000861-32-DE01/12/201523 July 2018Standard-armed controlled study to assess the impact of oral Pirfenidone for progressive, non-IPF Lung Fibrosis (RELIEF)Exploring Efficacy and Safety of oral Pirfenidone for progressive, non-IPF Lung Fibrosis (RELIEF) A randomized, double-blind, placebo-controlled, parallel group, multi-center, phase II trial - RELIEF1.Fibrotic NSIP., 2.Chronic Hypersensitivity Pneumonitis 3. Lung fibrosis associated with collagen / vascular diseases, 4.Asbestos-induced lung fibrosis
MedDRA version: 20.0 Level: LLT Classification code 10022612 Term: Interstitial lung fibrosis System Organ Class: 100000004855
MedDRA version: 20.0 Level: LLT Classification code 10035754 Term: Pneumonitis hypersensitivity System Organ Class: 100000004855
MedDRA version: 20.0 Level: LLT Classification code 10025088 Term: Lung fibrosis System Organ Class: 100000004855
MedDRA version: 20.0 Level: LLT Classification code 10022617 Term: Interstitial pneumonia System Organ Class: 100000004855 ;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
Trade Name: Esbriet® (Pirfenidon)
Product Code: PZN 8881655(RochePharma AG)
Pharmaceutical Form: Capsule, hard
INN or Proposed INN: PIRFENIDONE
CAS Number: 53179-13-8
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 267-
Pharmaceutical form of the placebo: Capsule, hard
Route of administration of the placebo: Oral use
Justus Liebig Universität GiessenNot RecruitingFemale: yes
Male: yes
374Phase 2Germany
87NCT02460588December 201518 January 2018Cyclophosphamide for Acute Exacerbation of Idiopathic Pulmonary FibrosisCyclophosphamide Added to Corticosteroid in the Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis: a Placebo-controlled Randomized TrialIdiopathic Pulmonary FibrosisDrug: Cyclophosphamide;Drug: Placebo;Drug: Corticosteroid (prednisolone)Assistance Publique - Hôpitaux de ParisRecruiting18 YearsN/AAll120Phase 3France
88NCT02551068December 20153 June 2019High Oxygen Delivery to Preserve Exercise Capacity in Idiopathic Pulmonary Fibrosis Patients Treated With NintedanibHigh Oxygen Delivery to Preserve Exercise Capacity in IPF Patients Treated With Nintedanib: The HOPE-IPF StudyIdiopathic Pulmonary FibrosisOther: 60% Oxygen;Other: Standard of CareUniversity of British ColumbiaBoehringer IngelheimRecruiting19 YearsN/AAll88N/ACanada
89JPRN-UMIN0000194362015/10/162 April 2019Randomized Phase 2 study of Nintedanib and Pirfenidone versus Nintedanib following a clinically meaningful decline in forced vital capacity in patients with idiopathic pulmonary fibrosis administering pirfenidoneidiopathic pulmonary fibrosisNintedanib+pirfenidone group;
Nintedanib 150mg twice daily
Pirfenidone 600-1800mg/day
Nintedanib group;
Nintedanib 150mg twice daily
Kanagawa Cardiovascular and Respiratory CenterNot Recruiting40years-oldNot applicableMale and Female60Phase 2Japan
90NCT01462006October 20153 December 2018Double-blind Placebo-controlled Pilot Study of Sirolimus in Idiopathic Pulmonary Fibrosis (IPF)Double-blind Placebo-controlled Pilot Study of Sirolimus in IPFIdiopathic Pulmonary Fibrosis;Diffuse Parenchymal Lung Disease;Interstitial Lung DiseaseDrug: sirolimus;Other: PlaceboUniversity of VirginiaNational Heart, Lung, and Blood Institute (NHLBI)Not recruiting21 Years85 YearsAll32N/AUnited States
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
91NCT02607722August 31, 201522 October 2019All-Case Surveillance of Ofev in Patients With IPF in JapanThe Special Drug Use-results Survey (All-Case Surveillance) of Ofev® Capsules in Patients With Idiopathic Pulmonary Fibrosis (IPF) in JapanIdiopathic Pulmonary FibrosisDrug: NintedanibBoehringer IngelheimNot recruitingN/AN/AAll5674N/AJapan
92EUCTR2015-000640-42-FR26/08/20157 September 2015Safety, tolerability and PK of nintedanib in combination with pirfenidone in IPFA twelve week, open-label, randomised, parallel-group study evaluating safety, tolerability and pharmacokinetics (PK) of oral nintedanib in combination with oral pirfenidone, compared to treatment with nintedanib alone, in patients with idiopathic pulmonary fibrosis (IPF) - Safety, tolerability and PK of nintedanib in combination with pirfenidone in IPFIdiopathic Pulmonary Fibrosis
MedDRA version: 18.0 Level: PT Classification code 10021240 Term: Idiopathic pulmonary fibrosis System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders ;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
Trade Name: Ofev
Product Name: Ofev 100 mg capsule
Product Code: nintedanib
Pharmaceutical Form: Capsule, soft
INN or Proposed INN: nintedanib
CAS Number: 656247-17-5
Other descriptive name: NINTEDANIB
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 100-
Trade Name: Ofev
Product Name: Ofev 150 mg capsule
Product Code: nintedanib
Pharmaceutical Form: Capsule, soft
INN or Proposed INN: nintedanib
CAS Number: 656247-17-5
Other descriptive name: NINTEDANIB
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 150-
Trade Name: Esbriet
Product Name: pirfenidone
Product Code: pirfenidone
Pharmaceutical Form: Capsule, hard
INN or Proposed INN: PIRFENIDONE
CAS Number: 53179-13-8
Current Sponsor code: PIRFENIDONE
Other descriptive name: PIRFENIDONE
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 267-
Boehringer Ingelheim FranceAuthorisedFemale: yes
Male: yes
135United States;France;Canada;Netherlands;Germany;Italy
93NCT02502097August 20, 201516 December 2017A Study of Gefapixant (AF-219/MK-7264) in Subjects With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough (MK-7264-016)A Randomized Placebo-Controlled Study to Assess the Efficacy and Safety of AF-219, a P2X3 Receptor Antagonist, in Subjects With Idiopathic Pulmonary Fibrosis (IPF) With Persistent CoughIdiopathic Pulmonary Fibrosis;CoughDrug: Gefapixant first, then Placebo;Other: Placebo first, then GefapixantAfferent Pharmaceuticals, Inc.Not recruiting40 YearsN/AAll51Phase 2United States
94NCT02477709July 20, 20151 July 2019A Study to Assess the Tolerability of a Single Dose of Gefapixant (AF-219/MK-7264) in Subjects With Idiopathic Pulmonary Fibrosis (IPF)A Study to Assess the Tolerability of a Single Dose of AF-219, a P2X3 Receptor Antagonist, in Subjects With Idiopathic Pulmonary Fibrosis (IPF)Idiopathic Pulmonary FibrosisDrug: GefapixantAfferent Pharmaceuticals, Inc.Not recruiting40 YearsN/AAll6Phase 2United States
95NCT01841307July 201525 February 2019Cromolyn Detection of Silent AspirationDevelopment and Validation of Test for Gastro-esophageal Reflux and AspirationGastroesophageal Reflux;Respiratory Aspiration;Idiopathic Pulmonary Fibrosis;Lung TransplantationDrug: Cromolyn SodiumUniversity of California, San FranciscoAradign Corportation;National Heart, Lung, and Blood Institute (NHLBI)Not recruiting18 Years70 YearsAll16Phase 1United States
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
96NCT02538536July 201529 April 2019A Phase 2 Study to Evaluate the Safety and Tolerability of PBI-4050 in Patients With Idiopathic Pulmonary Fibrosis (IPF)A Phase 2, Open-label, Single Arm, Exploratory, Observational Study to Evaluate the Safety and Tolerability of PBI-4050 in Patients With Idiopathic Pulmonary Fibrosis (IPF)Idiopathic Pulmonary Fibrosis (IPF)Drug: PBI4050ProMetic BioSciences Inc.Not recruiting40 YearsN/AAll41Phase 2Canada
97EUCTR2014-004782-24-NL06/05/201510 July 2015A study to test intravenous PRM-151 for safety and to see how PRM-151 acts in the body and blood of people with idiopathic pulmonary fibrosis (IPF) - a disorder where lung tissue becomes damaged and scarred making it difficult to breathe.A Pilot Trial to Evaluate the Efficacy of PRM-151 in Subjects with Idiopathic Pulmonary Fibrosis (IPF).Idiopathic Pulmonary Fibrosis (IPF)
MedDRA version: 17.1 Level: PT Classification code 10021240 Term: Idiopathic pulmonary fibrosis System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders ;Therapeutic area: Body processes [G] - Circulatory and Respiratory Physiological Phenomena [G09]
Product Code: PRM-151
Pharmaceutical Form: Solution for infusion
Pharmaceutical form of the placebo: Solution for infusion
Route of administration of the placebo: Intravenous use
Promedior incAuthorisedFemale: yes
Male: yes
60Netherlands
98NCT02345070May 1, 201525 June 2018Efficacy and Safety of SAR156597 in the Treatment of Idiopathic Pulmonary FibrosisEfficacy and Safety of SAR156597 in the Treatment of Idiopathic Pulmonary Fibrosis (IPF): A Randomized, Double-blind, Placebo-controlled, 52-week Dose-ranging StudyIdiopathic Pulmonary FibrosisDrug: SAR156597;Drug: placeboSanofiNot recruiting40 YearsN/AAll327Phase 2United States;Argentina;Australia;Canada;Chile;Colombia;Czechia;Denmark;France;Germany;Greece;Israel;Italy;Korea, Republic of;Mexico;Portugal;Spain;Turkey;United Kingdom;Czech Republic
99NCT02267655May 201516 December 20173 Part Study to Assess Inhaled Nitric Oxide on Functional Pulmonary Imaging in Subj. Pulmonary Hypertension Associated w/ COPD and IPFAn Exploratory, 3-Part, Clinical Study to Assess the Effect of Pulsed, Inhaled Nitric Oxide (iNO) on Functional Pulmonary Imaging Parameters in Subjects With World Health Organization (WHO) Group 3 Pulmonary Hypertension (PH) Associated With Chronic Obstructive Pulmonary Disease (COPD) on Long-Term Oxygen Therapy (LTOT) (Part 1) and in Subjects With WHO Group 3 PH Associated With Idiopathic Pulmonary Fibrosis (IPF) on LTOT (Part 2 and Part 3)Pulmonary Hypertension;Chronic Obstructive Pulmonary Disease;Idiopathic Pulmonary FibrosisDrug: inhaled Nitric Oxide - 30 mcg/kg IBW/hr;Drug: inhaled Nitric Oxide 5,10,15 mcg/Kg IBW/hr;Drug: inhaled nitric oxide 75 mcg/kg IBW/hrBellerophonNot recruiting40 Years80 YearsAll8Phase 1Belgium
100NCT02478268May 201527 May 2019Using MRI to Visualize Regional Therapy Response in Idiopathic Pulmonary FibrosisUsing MRI to Visualize Regional Therapy Response in Idiopathic Pulmonary FibrosisIdiopathic Pulmonary FibrosisDrug: Hyperpolarized 129-Xenon gas;Device: MRIBastiaan DriehuysUniversity of Wisconsin, Madison;National Heart, Lung, and Blood Institute (NHLBI)Recruiting18 YearsN/AAll79Phase 1United States
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
101JPRN-UMIN0000168262015/03/317 October 2019The evaluation of oxidative stress and the effect of pirfenidone in patients with idiopathic pulmonary fibrosis.The evaluation of oxidative stress and the effect of pirfenidone in patients with idiopathic pulmonary fibrosis. - The evaluation of oxidative stress and the effect of pirfenidone in patients with idiopathic pulmonary fibrosis.Idiopathic pulmonary fibrosis (IPF)Pirfenidone
Observation
National Hospital Organization Ibarakihigashi National HospitalRecruitingNot applicableNot applicableMale and Female40Not applicableJapan
102NCT02397005March 20154 February 2019Study of the Tolerability and Pharmacokinetic of ZL-2102 With an Investigation of Food Effect in Healthy Male SubjectsRandomized, Double-blind, Placebo-controlled Study of the Tolerability and Pharmacokinetics of Ascending Single and 14-day Repeated Oral Doses of ZL-2102 With a Pilot Investigation of Food Effect in Healthy Male SubjectsChronic Obstructive Pulmonary Disease;Asthma;Idiopathic Pulmonary FibrosisDrug: ZL-2102;Drug: Placebo matching ZL-2102Zai Lab Pty. Ltd.Not recruiting18 Years45 YearsMale120Phase 1Australia
103EUCTR2014-004025-40-NL06/02/20154 August 2015Treatment of chronic cough with PA101.Treatment of Chronic Idiopathic Cough (CIC) and Chronic Cough in patients with Idiopathic Pulmonary Fibrosis (IPF) with PA101. - Treatment of chronic cough with PA101Chronic Idiopathic Cough and Chronic Cough in Idiopathic Pulmonary Fibrosis
MedDRA version: 18.0 Level: LLT Classification code 10066656 Term: Chronic cough System Organ Class: 100000004855 ;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
Product Name: Disodium Cromoglycate [cromolyn sodium]
Product Code: PA101
Pharmaceutical Form: Nebulisation solution
INN or Proposed INN: Not available
CAS Number: 15826-37-6
Current Sponsor code: PA101
Other descriptive name: Disodium cromoglycate (DSCG)
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 40-
Pharmaceutical form of the placebo: Nebulisation solution
Route of administration of the placebo: Inhalation use
Patara PharmaAuthorisedFemale: yes
Male: yes
48Netherlands;United Kingdom
104NCT02412020February 201514 March 2016Treatment of Refractory Chronic Cough With PA101Treatment of Chronic Idiopathic Cough and Chronic Cough in Patients With Idiopathic Pulmonary Fibrosis With PA101Refractory Chronic CoughDrug: PA101;Drug: PlaceboPatara PharmaNot recruiting18 Years75 YearsBoth52Phase 2Netherlands;United Kingdom
105ChiCTR-OOC-150058412015-01-0118 April 2017Montelukast Sodium Tablets treatment clinical study for intractable cough by idiopathic pulmonary fibrosisMontelukast Sodium Tablets treatment clinical study for intractable cough by idiopathic pulmonary fibrosisIdiopathic pulmonary fibrosisMontelukast Sodium Tablets treatment group :Montelukast Sodium Tablets: oral, 1 tablets each time (10mg), 1 time a day, at bedtime, for a period of 12 weeks;control group :Don't take Montelukast Sodium Tablets;Shanghai Pulmonary HospitalRecruiting5080BothMontelukast Sodium Tablets treatment group :30;control group :30;Other
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
106ChiCTR-OOC-150058622015-01-0118 April 2017The clinical study of the treatment by Granulocyte colony stimulating factor for idiopathic pulmonary fibrosis.An Open-label, parallel, randomized controlled clinical study of the treatment by Granulocyte colony stimulating factor for idiopathic pulmonary fibrosis.idiopathic pulmonary fibrosistreatment group:subcutaneous injection of Granulocyte colony stimulating factor termly;control group:no processing;Shanghai Pulmonary HospitalRecruiting5080Bothtreatment group:50;control group:50;OtherChina
107JPRN-UMIN0000155082015/01/0121 May 2019A prospective randomized, multicenter trial evaluating the efficacy and safety of combined therapy with pirfenidone and inhaled N-acetylcysteine for idiopathic pulmonary fibrosis.A prospective randomized, multicenter trial evaluating the efficacy and safety of combined therapy with pirfenidone and inhaled N-acetylcysteine for idiopathic pulmonary fibrosis. - Combined therapy with pirfenidone and inhaled N-acetylcysteine for idiopathic pulmonary fibrosis.Idiopathic pulmonary fibrosisUsing Micro Air nebulizers and vibration mesh technology (NE-U07, Omron, Tokyo, Japan), patients receiving NAC combined with pirfenidone were treated twice daily with 352.4 mg of inhaled NAC, which was diluted with saline to a total volume of 6 mL for 48 weeks.
Pirfenidone 1200-1800mg (control group)
Grant for Research on Diffuse Lung Disease from the Ministry of Health, Labour and Welfare of Japan.Not Recruiting40years-oldNot applicableMale and Female150Not selectedJapan
108NCT02485886January 201516 December 201768Ga-BMV101 PET/CT in Patients With Idiopathic Pulmonary FibrosisSafety and Diagnostic Performance of 68Ga-BMV101 PET/CT in Patients With Idiopathic Pulmonary FibrosisIdiopathic Pulmonary FibrosisDrug: 68Ga-BMV101Peking Union Medical College HospitalStanford UniversityNot recruiting18 YearsN/AAll20Early Phase 1China
109JPRN-JapicCTI-14270824/10/20142 April 2019A phase II study of LebrikizumabA PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, STUDY TO ASSESS THE EFFICACY AND SAFETY OF LEBRIKIZUMAB IN PATIENTS WITH IDIOPATHIC PULMONARYIDIOPATHIC PULMONARY FIBROSISIntervention name : RO5490255
INN of the intervention : Lebrikizumab
Dosage And administration of the intervention : 250mg SC injection every 4 weeks
Control intervention name : Placebo
Dosage And administration of the control intervention : SC injection every 4 weeks
Chugai Pharmaceutical Co., Ltd.40BOTH480Phase 2
110NCT04016168October 22, 201422 July 2019Idiopathic Pulmonary Fibrosis and Serum BankIdiopathic Pulmonary Fibrosis and Serum BankIdiopathic Pulmonary Fibrosis;Lung Diseases, InterstitialBiological: Blood sample collectionRennes University HospitalRecruiting18 YearsN/AAll500N/AFrance
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
111NCT02168530October 201414 November 2016A Study of Oral Vismodegib for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)Idiopathic Pulmonary FibrosisDrug: placebo;Drug: vismodegibHoffmann-La RocheNot recruiting40 YearsN/ABoth0Phase 2Australia;France;Germany;Israel;Korea, Republic of;Mexico;Peru;United States
112EUCTR2014-003423-21-BE29/09/201410 July 2017Evaluation of impact of inhaled nitric oxide on pulmonary vessel blood volume measured by high resolution computed tomography (HRCT) in subjects with World Health Organization (WHO) Group 3 Pulmonary Hypertension (PH) Associated with Chronic Obstructive Pulmonary Disease (COPD) on Long-Term Oxygen Therapy (LTOT) (Part 1) and in subjects with WHO Group 3 Pulmonary Hypertension (PH) Associated with Idiopathic pulmonary fibrosis (IPF) on Long-Term Oxygen Therapy (LTOT) (Part 2).An Exploratory, Two-Part, Clinical Study to Assess the Effect of Pulsed, Inhaled Nitric Oxide (iNO) on Functional Pulmonary Imaging Parameters in Subjects with World Health Organization (WHO) Group 3 Pulmonary Hypertension (PH) Associated with Chronic Obstructive Pulmonary Disease (COPD) on Long-Term Oxygen Therapy (LTOT) (Part 1) and in Subjects with WHO Group 3 PH associated with Idiopathic pulmonary fibrosis (IPF) on LTOT (Part 2).Part 1: Pulmonary Hypertension (PH) Associated with Chronic Obstructive Pulmonary Disease (COPD) Part 2: Pulmonary Hypertension (PH) Associated with Idiopathic pulmonary fibrosis (IPF)
MedDRA version: 18.1 Level: PT Classification code 10021240 Term: Idiopathic pulmonary fibrosis System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders
MedDRA version: 18.1 Level: LLT Classification code 10010952 Term: COPD System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders
MedDRA version: 18.1 Level: PT Classification code 10009033 Term: Chronic obstructive pulmonary disease System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders
MedDRA version: 18.1 Level: PT Classification code 10037400 Term: Pulmonary hypertension System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders
MedDRA version: 18.1 Level: HLT Classification code 10037401 Term: Pulmonary hypertensions System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders ;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
Trade Name: INOmax 400ppm mol/mol inhalation gas
Product Name: INO
Pharmaceutical Form: Pressurised inhalation
INN or Proposed INN: NITRIC OXIDE
CAS Number: 10102-43-9
Current Sponsor code: IK-7002
Concentration unit: mg/kg/h milligram(s)/kilogram/hour
Concentration type: up to
Concentration number: 0.075-
Pharmaceutical form of the placebo: Pressurised inhalation
Route of administration of the placebo: Inhalation use
Bellerophon Pulse Technologies LLCNot RecruitingFemale: yes
Male: yes
Phase 1;Phase 2Belgium
113NCT02257177September 201416 December 2017RCT (Randomized Control Trial) of TD139 vs Placebo in HV's (Human Volunteers) and IPF PatientsA Placebo-controlled RCT in HV's Investigating the Safety, Tolerability and PK (Pharmacokinetic) of TD139, a Galectin-3 Inhibitor, Followed by an Expansion Cohort Treating Subjects With Idiopathic Pulmonary Fibrosis (IPF)Idiopathic Pulmonary FibrosisDrug: Inhaled TD139;Drug: PlaceboGalecto Biotech ABNot recruiting45 Years85 YearsAll60Phase 1/Phase 2United Kingdom
114NCT02173145August 19, 20149 September 2019Azithromycin in Idiopathic Pulmonary FibrosisAzithromycin for the Treatment of Cough in Idiopathic Pulmonary Fibrosis- a Clinical TrialIdiopathic Pulmonary Fibrosis;CoughDrug: azithromycin;Drug: placeboUniversity Hospital Inselspital, BerneUniversity of BernNot recruiting18 YearsN/AAll27N/ASwitzerland
115NCT02135380August 201419 February 2015Evaluate Safety and Efficacy of Intravenous Autologous ADMSc for Treatment of Idiopathic Pulmonary FibrosisA Prospective, Multicentric, Phase I/II, Open Label, Randomized, Interventional Study to Evaluate the Safety and Efficacy of Intravenous Autologous Adipose Derived Adult Stem Cells for Treatment of Idiopathic Pulmonary Fibrosis (IPF).Idiopathic Pulmonary FibrosisBiological: Autologous Stromal Vascular Fraction (SVF);Biological: Autologous Adipose Derived MSCs (ADMSCs);Other: ControlKasiak Research Pvt. Ltd.Recruiting30 Years70 YearsBoth60Phase 1/Phase 2India
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
116NCT02230982August 201425 February 2019Expanded Access Program of Nintedanib in Patients With Idiopathic Pulmonary FibrosisMulti-center Open-label Expanded Access Program of Oral Nintedanib 150 mg Twice Daily in Patients With Idiopathic Pulmonary FibrosisIdiopathic Pulmonary FibrosisDrug: nintedanibBoehringer IngelheimNot recruiting40 YearsN/AAllN/ABrazil
117NCT02141087July 20143 August 2015Expanded Access Program (EAP): Allow Patients in the US With Idiopathic Pulmonary Fibrosis Access to PirfenidoneA Treatment Protocol to Allow Patients in the US With Idiopathic Pulmonary Fibrosis Access to PirfenidoneIdiopathic Pulmonary FibrosisDrug: PirfenidoneGenentech, Inc.Not recruiting18 YearsN/ABothN/A
118NCT02248064July 201423 February 2016Auto-titrating Oxygen in Chronic Respiratory FailureThe Assessment of Intelligent Oxygen Therapy (iO2t) in Patients With Chronic Obstructive Pulmonary Disease (COPD) and Idiopathic Pulmonary Fibrosis (IPF)Chronic Obstructive Pulmonary Disease;Idiopathic Pulmonary FibrosisDevice: Auto-titrating oxygen systemImperial College LondonNot recruiting18 YearsN/ABoth26N/AUnited Kingdom
119NCT02622477June 201416 December 2017Clinical Progression of Mild to Moderate Idiopathic Pulmonary Fibrosis (IPF) Under a Therapy With Esbriet® (Pirfenidone)Clinical Course of Treatment With ESBRIET in Patients With Mild to Moderate IPFIdiopathic Pulmonary FibrosisDrug: PirfenidoneHoffmann-La RocheInterMune Deutschland GmbHNot recruitingN/AN/AAll12N/AGermany
120NCT02036970May 201414 January 2019Bardoxolone Methyl Evaluation in Patients With Pulmonary Hypertension (PH) - LARIATA Dose-Ranging Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Pulmonary HypertensionPulmonary Arterial Hypertension;Pulmonary Hypertension;Interstitial Lung Disease;Idiopathic Interstitial Pneumonia;Idiopathic Pulmonary Fibrosis;Sarcoidosis;Respiratory Bronchiolitis Associated Interstitial Lung Disease;Desquamative Interstitial Pneumonia;Cryptogenic Organizing Pneumonia;Acute Interstitial Pneumonitis;Idiopathic Lymphoid Interstitial Pneumonia;Idiopathic Pleuroparenchymal FibroelastosisDrug: Bardoxolone methyl;Drug: PlaceboReata Pharmaceuticals, Inc.Not recruiting18 Years75 YearsAll166Phase 2United Kingdom;Spain;United States;Germany
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
121NCT02171156May 201416 December 2017Expanded Access Program of Nintedanib in Patients With Idiopathic Pulmonary Fibrosis (EAP)Multi-center Open-label Expanded Access Program of Oral Nintedanib 150 mg Twice Daily in Patients With Idiopathic Pulmonary FibrosisIdiopathic Pulmonary FibrosisDrug: nintedanibBoehringer IngelheimNot recruiting40 YearsN/AAllN/AUnited States
122NCT02048644March 201422 July 2019Effect of Fostair® on Biomarkers of Platelet Adhesion in Idiopathic Pulmonary FibrosisA Randomized, Double-blind, Placebo-controlled, Crossover Study to Assess the Effect of 28 Day Treatment With Fostair® Pressurized Metered-dose Inhaler (pMDI) 200/12 on Biomarkers of Platelet Adhesion in Patients With Idiopathic Pulmonary FibrosisIdiopathic Pulmonary FibrosisDrug: placebo;Drug: fostairHull and East Yorkshire Hospitals NHS TrustChiesi Farmaceutici S.p.A.Not recruiting40 Years85 YearsAll20Phase 2United Kingdom
123NCT02055456February 201414 December 2015Nandrolone Decanoate in the Treatment of TelomeropathiesMale Hormones for Telomere Related DiseasesAplastic Anemia;Bone Marrow Failure Syndromes;Idiopathic Pulmonary Fibrosis;Telomere ShorteningDrug: Nandrolone DecanoateUniversity of Sao PauloConselho Nacional de Desenvolvimento Científico e TecnológicoRecruiting2 YearsN/ABoth20Phase 1/Phase 2Brazil
124NCT01969409January 20144 March 2019Autoantibody Reduction Therapy in Patients With Idiopathic Pulmonary FibrosisAutoantibody Reduction Therapy in Patients With Idiopathic Pulmonary Fibrosis (ART-IPF)Ambulatory IPFDrug: Rituximab;Drug: PlaceboUniversity of Alabama at BirminghamNational Institutes of Health (NIH)Not recruiting50 Years85 YearsAll58Phase 2United States
125NCT02036580January 201416 December 2017D2212C00002 J-Phase II StudyA Phase 2, Multicenter, Double-Blind Within Cohort, Dose-escalation Study to Evaluate the Safety and Tolerability of Multiple Doses of CAT-354 (Tralokinumab) in Japanese Patients With Idiopathic Pulmonary FibrosisIdiopathic Pulmonary FibrosisBiological: tralokinumab cohort 1;Biological: tralokinumab cohort 2;Other: PlaceboAstraZenecaMedImmune LLCNot recruiting50 YearsN/AAll37Phase 2Japan
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
126NCT02009293December 20139 January 2017The Effect of Pirfenidone on Cough in Patients With Idiopathic Pulmonary FibrosisObservational Study of the Effect of Pirfenidone on Cough in Patients With Idiopathic Pulmonary FibrosisIdiopathic Pulmonary FibrosisOther: Cough monitorErasmus Medical CenterUniversity of Catania;University of Lyon;King's College Hospital NHS Trust;Royal Brompton & Harefield NHS Foundation TrustNot recruiting40 Years85 YearsBoth43N/AFrance;Italy;Netherlands
127NCT01979952November 26, 201311 June 2018Nintedanib Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis (IPF)A Six Month Double Blind Randomized Placebo Controlled Trial Followed by Each Arm Being Converted to Oral Nintedanib 150 mg Twice Daily Comparing the Effect on High Resolution Computerized Tomography Quantitative Lung Fibrosis Score, Lung Function, Six Minute Walk Test Distance and St. George's Respiratory Questionnaire After Six Months of Treatment in Patients With Idiopathic Pulmonary Fibrosis With Continued Evaluations Over a Period of up to Eighteen MonthsIdiopathic Pulmonary FibrosisDrug: Matching Placebo;Drug: NintedanibBoehringer IngelheimNot recruiting40 YearsN/AAll113Phase 3United States;Canada;Turkey
128NCT01777737November 25, 201316 December 2017Study to Test the Validity of the Treatment of Idiopathic Pulmonary Fibrosis With CotrimoxazolePilot Study Phase III to Evaluate the Efficacy and Safety of Trimethoprim-sulfamethoxazole in the Treatment of Idiopathic Pulmonary FibrosisIdiopathic Pulmonary FibrosisDrug: Cotrimoxazole;Drug: PlaceboFundación Pública Andaluza para la gestión de la Investigación en SevillaJunta de AndaluciaNot recruiting18 Years80 YearsAll3Phase 3Spain
129NCT02013700November 13, 201318 March 2019Allogeneic Human Cells (hMSC)in Patients With Idiopathic Pulmonary Fibrosis Via Intravenous Delivery (AETHER)A Phase I, Randomized, Blinded and Placebo-controlled Trial to Evaluate the Safety, Tolerability, and Potential Efficacy of Allogeneic Human Mesenchymal Stem Cell Infusion in Patients With Idiopathic Pulmonary FibrosisIdiopathic Pulmonary Fibrosis (IPF)Biological: Allogeneic Adult Human Mesenchymal Stem Cells (hMSCs);Biological: matched placeboJoshua M HareThe Lester And Sue Smith Foundation;The EMMES CorporationNot recruiting40 Years90 YearsAll9Phase 1United States
130JPRN-UMIN0000211092013/10/2110 September 2019Preventive effect of Sivelestat Na Hydrate on postoperative acute exacerbation of idiopathic interstitial pneumonia in the patient with lung cancerPreventive effect of Sivelestat Na Hydrate on postoperative acute exacerbation of idiopathic interstitial pneumonia in the patient with lung cancer - Preventive effect of Sivelestat Na Hydrate on postoperative acute exacerbation of idiopathic interstitial pneumonia in the patient with lung cancer (Sivelestat trial)idiopathic interstitial pneumonia (IIP)Control (n=30): intra- and postoperative management without Sivelestat
Trial (n=30): 7days administration of Sivelestat 0.2microgram/kgBW/hr div started from surgical operation
Japanese Northern East Area Thoracic Surgery Study Group (JNETS)Not Recruiting25years-old80years-oldMale and Female120Phase 3Japan
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
131NCT01872689October 13, 20133 September 2018A Study of Lebrikizumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)A Phase II, Randomized, Double-Blind, Placebo-Controlled, Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Idiopathic Pulmonary FibrosisIdiopathic Pulmonary FibrosisDrug: Lebrikizumab;Drug: Pirfenidone;Drug: PlaceboHoffmann-La RocheNot recruiting40 YearsN/AAll505Phase 2United States;Australia;Belgium;Canada;France;Germany;Italy;Japan;Mexico;Peru;Poland;Spain;United Kingdom
132EUCTR2013-003301-26-GB20/09/20133 April 2017A clinical trial to assess whether a treatment reducing acid production in the stomach (omeprazole) can reduce cough in patients with scarring of the lungs.A randomised placebo-controlled pilot trial of omeprazole in idiopathic pulmonary fibrosis (IPF) - Pilot trial of omeprazole in idiopathic pulmonary fibrosis (Acronym :Idiopathic Pulmonary Fibrosis (IPF)
MedDRA version: 19.0 Level: PT Classification code 10021240 Term: Idiopathic pulmonary fibrosis System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders ;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
Trade Name: Omeprazole (UK licensed generic product)
Product Name: Omeprazole
Pharmaceutical Form: Gastro-resistant capsule, hard
INN or Proposed INN: Omeprazole
CAS Number: 73590-58-6
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 20-
Pharmaceutical form of the placebo: Capsule, hard
Route of administration of the placebo: Oral use
Newcastle Upon Tyne Hospitals NHS Foundation TrustNot RecruitingFemale: yes
Male: yes
Phase 2United Kingdom
133EUCTR2012-000564-14-BE18/06/201317 August 2015A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of the Safety and Tolerability of N–Acetylcysteine in Patients with Idiopathic Pulmonary Fibrosis with Background Treatment of PirfenidoneA Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of the Safety and Tolerability of N–Acetylcysteine in Patients with Idiopathic Pulmonary Fibrosis with Background Treatment of Pirfenidone - PANORAMAPatients with Idiopathic Pulmonary Fibrosis (IPF)
MedDRA version: 17.0 Level: PT Classification code 10021240 Term: Idiopathic pulmonary fibrosis System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders ;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
Trade Name: Fluimucil® 600 mg effervescent tablets
Pharmaceutical Form: Effervescent tablet
INN or Proposed INN: ACETYLCYSTEINE
Other descriptive name: N-Acetylcysteine, (NAC)
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 600-
Pharmaceutical form of the placebo: Effervescent tablet
Route of administration of the placebo: Oral use
InterMune International AG.Not RecruitingFemale: yes
Male: yes
120Phase 2Belgium;Denmark;Austria;Germany;United Kingdom;Italy;Sweden
134NCT01890265June 201313 May 2019Evaluate the Safety and Efficacy of FG-3019 in Patients With Idiopathic Pulmonary FibrosisA Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of FG-3019 in Patients With Idiopathic Pulmonary FibrosisIdiopathic Pulmonary FibrosisDrug: FG-3019;Drug: Placebo;Drug: Sub-study: Pirfenidone;Drug: Sub-study: Nintedanib;Drug: Sub-study: FG-3019;Drug: Sub-study: PlaceboFibroGenNot recruiting40 Years80 YearsAll160Phase 2United States;Australia;Bulgaria;Canada;India;New Zealand;South Africa
135EUCTR2012-005409-38-ES19/04/201311 December 2017First study to test the validity of the treatment of the disease called idiopathic pulmonary fibrosis, which causes inflammation and fibrosis (scarring) of the lung tissue, with a drug called cotrimoxazole.Pilot study phase III to evaluate the efficacy and safety of Trimethoprim-sulfamethoxazole in the treatment of idiopathic pulmonary fibrosisAmbulatory patients, men and women, with well-established diagnosis of idiopathic pulmonary fibrosis.
MedDRA version: 14.1 Level: PT Classification code 10021240 Term: Idiopathic pulmonary fibrosis System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders ;Therapeutic area: Diseases [C] - Parasitic Diseases [C03]
Trade Name: SEPTRIN
Pharmaceutical Form: Tablet
INN or Proposed INN: TRIMETHOPRIM
Other descriptive name: TRIMETHOPRIM
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 80-
INN or Proposed INN: SULFAMETHOXAZOLE
CAS Number: 723-46-6
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 400-
Pharmaceutical form of the placebo: Tablet
Route of administration of the placebo: Oral use
Fundación Pública Andaluza para la Gestión de la Investigación en Salud de Sevilla (FISEVI)Not RecruitingFemale: yes
Male: yes
56Phase 3Spain
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
136EUCTR2012-005794-31-GB25/03/201318 November 2013A study to assess the effect of a single-does of VRP700 by inhalation to reduce the frequency and severity of cough in adults with Idiopathic Pulmonary Fibrosis (IPF)A randomised, double-blind, placebo-controlled crossover study to assess the efficacy of a single dose of 100mg of VRP700 by inhalation in reducing the frequency and severity of cough in adult patients with Idiopathic Pulmonary Fibrosis - EPOChChronic cough in Idiopathic Pulmonary Fibrosis
MedDRA version: 16.1 Level: LLT Classification code 10066656 Term: Chronic cough System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders
MedDRA version: 16.1 Level: PT Classification code 10011224 Term: Cough System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders ;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
Product Name: VRP700
Product Code: VRP700
Pharmaceutical Form: Inhalation powder
Current Sponsor code: VRP700
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 10-
Pharmaceutical form of the placebo: Inhalation vapour, solution
Route of administration of the placebo: Inhalation use
Verona Pharma plcAuthorisedFemale: yes
Male: yes
United Kingdom
137NCT01725139March 8, 201316 December 2017A Proof of Mechanism Study With GSK2126458 in Patients With Idiopathic Pulmonary Fibrosis (IPF)A Randomised, Placebo-controlled, Double-blind, Repeat Dose Escalation Study With GSK2126458 in Patients With Idiopathic Pulmonary Fibrosis (IPF)Idiopathic Pulmonary FibrosisDrug: GSK2126458;Drug: PlaceboGlaxoSmithKlineNot recruiting45 YearsN/AAll17Phase 1United Kingdom
138NCT01919827March 201311 June 2018Study of Autologous Mesenchymal Stem Cells to Treat Idiopathic Pulmonary FibrosisTreatment of Idiopathic Pulmonary Fibrosis With Bone Marrow Derived Mesenchymal Stem CellsIdiopathic Pulmonary FibrosisBiological: Endobronchial infusion of adult mesenchymal stem cells;Biological: Autologous mesenchymal stem cells derived from bone marrowClinica Universidad de Navarra, Universidad de NavarraNot recruiting30 Years80 YearsAll17Phase 1Spain
139NCT02594839February 201322 January 2018Safety and Efficacy of Allogeneic Mesenchymal Stem Cells in Patients With Rapidly Progressive Interstitial Lung DiseaseA Phase I-II Study to Evaluate Safety and Efficacy of Allogeneic Bone-Marrow Mesenchymal Stem Cells in Patients With Rapidly Progressive Interstitial Lung DiseaseIdiopathic Interstitial Pneumonia;Interstitial Lung Disease;Idiopathic Pulmonary FibrosisDrug: Bone marrow mesenchymal stem cells;Drug: PlaceboFederal Research Clinical Center of Federal Medical & Biological Agency, RussiaNot recruiting20 Years80 YearsAll20Phase 1/Phase 2Russian Federation
140NCT01766817January 31, 201326 August 2019Safety and Efficacy of a Lysophosphatidic Acid Receptor Antagonist in Idiopathic Pulmonary FibrosisSafety and Efficacy of a Lysophosphatidic Acid Receptor Antagonist in Idiopathic Pulmonary FibrosisIdiopathic Pulmonary FibrosisDrug: BMS-986020;Drug: Placebo matching with BMS-986020Bristol-Myers SquibbNot recruiting40 Years90 YearsAll325Phase 2United States;Australia;Chile;Colombia;Mexico;Peru
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
141NCT01769196January 31, 201316 December 2017Study to Assess the Efficacy and Safety of Simtuzumab (GS-6624) in Adults With Idiopathic Pulmonary Fibrosis (IPF)A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of Simtuzumab (GS-6624) in Subjects With Idiopathic Pulmonary Fibrosis (IPF)Idiopathic Pulmonary FibrosisDrug: Simtuzumab;Drug: Simtuzumab placeboGilead SciencesNot recruiting45 Years85 YearsAll544Phase 2United States;Australia;Belgium;Canada;Czechia;France;Germany;Israel;Italy;Korea, Republic of;Poland;Spain;Switzerland;United Kingdom;Czech Republic
142JPRN-jRCTs05118014924/01/201322 July 2019CBDCA plus PTX for NSCLC (squamous) with IPPhase II study of carboplatin plus weekly paclitaxel for advanced squamous cell lung cancer with idiopathic interstitial pneumonia - IP001Squamous cell lung cancer
Lung cancer
Carboplatin (AUC=5) given on day1 and paclitaxel (70mg/m2) given on days 1,8,15 every 4weeks until disease progression or unmanageable toxicity.Yukimasa HatachiNot Recruiting>=20 age oldBoth40Phase 2none
143JPRN-jRCTs06118004617/01/201322 July 2019CBDCA, PTX and BV for NSCLC (non-sq) with IPPhase II study of carboplatin, weekly paclitaxel and bevacizumab for advanced non-squamous cell, non-small-cell lung cancer with idiopathic interstitial pneumonia - IP002Non-squamous, non-small cell lung cancer
Lung cancer
Carboplatin (AUC=5) given on day1, paclitaxel (70mg/m2) given on days 1,8,15 and bevacizumab (15mg/m2) on day 1 every 4weeks until disease progression or unmanageable toxicity.Yukimasa HatachiNot Recruiting20 year-old age oldNot applicable age oldBoth35Phase 2none
144JPRN-UMIN0000167062013/01/072 April 2019Efficacy and safety of inhaled N-acetylcysteine in idiopathic pulmonary fibrosisIdiopathic pulmonary fibrosisN-acetylcysteine was administered by inhalation at the dose of 352.4 mg b.i.d. via an ultrasonic nebulizer.Saitama Red Cross HospitalNot Recruiting40years-oldNot applicableMale and Female25Not selectedJapan
145JPRN-UMIN0000182482012/12/012 April 2019Phase II study of carboplatin plus weekly paclitaxel for advanced squamous cell lung cancer with idiopathic interstitial pneumoniaadvanced squamous cell lung cancer with idiopathic interstitial pneumoniaCarboplatin AUC = 5 , day1
Paclitaxel 70mg/m2, day1,8,15
4-6 cycle
IP lung cancer study groupRecruiting20years-oldNot applicableMale and Female40Not selectedJapan
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
146JPRN-UMIN0000183222012/12/012 April 2019Phase II study of carboplatin, weekly paclitaxel and bevacizumab for advanced non-squamous cell, non-small-cell lung cancer with idiopathic interstitial pneumoniaadvanced non-squamous cell, non-small-cell lung cancer with idiopathic interstitial pneumoniacarboplatin AUC = 5, day1
paclitaxel 70mg/m2, day1 ,8 ,15
bevacizumab 15mg/kg, day1
every 4 weeks, 4-6 cycle
IP lung cancer study groupRecruiting20years-oldNot applicableMale and Female35Not selectedJapan
147NCT01759511October 18, 201216 December 2017Long-Term Safety Study of GS-6624 in Adults With Idiopathic Pulmonary Fibrosis (IPF)A Phase 2, Long-Term Safety Study of GS-6624 in Adult Subjects With Idiopathic Pulmonary Fibrosis (IPF)Idiopathic Pulmonary FibrosisDrug: SimtuzumabGilead SciencesNot recruiting18 YearsN/AAll34Phase 2United States
148NCT01629667October 201216 December 2017A Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumab in Adults With Idiopathic Pulmonary FibrosisA Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumab in Adults With Idiopathic Pulmonary FibrosisIdiopathic Pulmonary FibrosisBiological: Tralokinumab;Other: PlaceboMedImmune LLCNot recruiting50 Years79 YearsAll409Phase 2United States;Australia;Canada;Israel;Korea, Republic of;Peru
149NCT01524068September 201218 January 2016A MultiCenter Study of Combined PEX, Rituximab, and Steroids in Acute Idiopathic Pulmonary Fibrosis ExacerbationsA Multicenter, Open-Label, Phase II Study of Combined Plasma Exchange (PEX), Rituximab, and Corticosteroids in Patients With Acute Idiopathic Pulmonary Fibrosis ExacerbationsIdiopathic Pulmonary FibrosisDrug: Standard Steroid Treatment;Drug: The Standard Steroid Treatment, Plasma Exchange and rituximabUniversity of PittsburghNot recruiting18 Years90 YearsBoth0Phase 2United States
150JPRN-UMIN0000085412012/07/302 April 2019The effect of pirfenidone on the mortality risk score in IPFidiopathic pulmonary fibrosispirfenidoneDepartment of Respiratory Medicine and Allergology, Kinki University Faculty of MedicineNot Recruiting20years-oldNot applicableMale and Female20Not applicableJapan
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
151NCT01371305July 16, 201211 June 2018STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, Dose-Escalation Study of STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)Idiopathic Pulmonary Fibrosis (IPF)Drug: BG00011;Drug: PlaceboBiogenNot recruiting18 Years84 YearsAll41Phase 2United States
152NCT01619085June 6, 201230 September 2019Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary FibrosisAn Open-label Extension Trial of the Long Term Safety of Oral BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis (IPF)Idiopathic Pulmonary FibrosisDrug: BIBF 1120Boehringer IngelheimNot recruiting40 YearsN/AAll752Phase 3United States;Australia;Belgium;Canada;Chile;China;Czechia;Finland;France;Germany;Greece;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Portugal;Russian Federation;Spain;Turkey;United Kingdom;Czech Republic
153JPRN-UMIN0000077742012/06/012 April 2019Phase II analysis for efficacy and safety of perioperative pirfenidone (Pirespa) therapy for patients with non-small cell lung cancer combined with idiopathic pulmonary fibrosis (IPF)non-small-cell lung cancer combined with idiopathic pulmonary fibrosisOral administration of pirfenidone starting from 4-6 weeks before the surgery.West Japan Oncology GroupNot Recruiting20years-old75years-oldMale and Female42Phase 2Japan
154EUCTR2011-002766-21-GR02/05/201222 January 2018Long term safety study of oral BIBF 1120 in patients with Idiopathic Pulmonary Fibrosis (IPF)An open-label extension trial of the long term safety of oral BIBF 1120 in patients with Idiopathic Pulmonary Fibrosis (IPF)Idiopathic Pulmonary Fibrosis
MedDRA version: 14.1 Level: PT Classification code 10021240 Term: Idiopathic pulmonary fibrosis System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders ;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
Product Name: BIBF 1120
Product Code: BIBF 1120
Pharmaceutical Form: Capsule, soft
INN or Proposed INN: nintedanib
Current Sponsor code: BIBF 1120
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 150-
Product Name: BIBF 1120
Product Code: BIBF 1120
Pharmaceutical Form: Capsule, soft
INN or Proposed INN: nintedanib
Current Sponsor code: BIBF 1120
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 100-
Boehringer Ingelheim HellasNot RecruitingFemale: yes
Male: yes
750Phase 3United States;Portugal;Greece;Spain;Ireland;Chile;Russian Federation;Israel;Italy;India;France;Australia;Netherlands;China;Korea, Republic of;Finland;Turkey;United Kingdom;Czech Republic;Mexico;Canada;Argentina;Brazil;Belgium;Germany;Japan
155NCT01457261April 201219 February 2015IPF Drug Deposition StudyA Study of the Pharmacokinetics and Deposition of Inhaled Salbutamol in Patients With Idiopathic Pulmonary Fibrosis (TOPICAL-IPF)Idiopathic Pulmonary FibrosisDrug: SalbutamolRoyal Brompton & Harefield NHS Foundation TrustGlaxoSmithKlineNot recruiting40 YearsN/ABoth10Phase 1United Kingdom
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
156NCT01529853April 201219 February 2015To Evaluate the Effect of Different Doses of SAR156597 Given to Patients With Idiopathic Pulmonary Fibrosis (IPF)Randomized, Double-blind, Placebo-controlled Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Ascending Repeated Doses of SAR156597 in Patients With Idiopathic Pulmonary Fibrosis (IPF)Idiopathic Pulmonary FibrosisDrug: SAR156597;Drug: PlaceboSanofiNot recruiting18 YearsN/ABoth24Phase 1/Phase 2United States;Canada;Chile;Mexico;Spain;Belgium
157EUCTR2011-003687-78-IT21/02/201224 February 2014Lanreotide Autogel for the treatment of patients with Idiopathic Pulmonary Fibrosis (IPF)Lanreotide Autogel for the treatment of patients with Idiopathic Pulmonary Fibrosis (IPF) - IPF/LANREOTIDE/2011-01Idiopathic Pulmonary Fibrosis
MedDRA version: 14.1 Level: PT Classification code 10021240 Term: Idiopathic pulmonary fibrosis System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders ;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
Pharmaceutical Form: Solution for injection
INN or Proposed INN: LANREOTIDE ACETATE
CAS Number: 127984-74-1
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 120-
Product Name: Gallium68-Dota-Noc
Product Code: NA
Pharmaceutical Form: Solution for injection
INN or Proposed INN: NA
CAS Number: NA
Current Sponsor code: 68Gallio-DOTA-NOC
Other descriptive name: NA
Concentration unit: MBq megabecquerel(s)
Concentration type: up to
Concentration number: 185-
AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHIAuthorisedFemale: yes
Male: yes
Italy
158NCT02699879February 16, 201216 December 2017Evaluation of Long-Term Safety of Pirfenidone (Esbriet) in Participants With Idiopathic Pulmonary Fibrosis (IPF)Post-Authorisation Safety Study of Esbriet® (Pirfenidone): A Prospective Observational Registry to Evaluate Long-Term Safety in a Real-World SettingIdiopathic Pulmonary FibrosisDrug: PirfenidoneHoffmann-La RocheNot recruitingN/AN/AAll1009N/AAustria;Denmark;Finland;France;Germany;Ireland;Italy;Norway;Sweden;United Kingdom
159NCT01504334January 201219 February 2015Safety and Efficacy Study of Pirfenidone to Treat Idiopathic Pulmonary Fibrosis(IPF)A Multicenter, Randomized, Double-blind, Placebo-controlled Trial for the Safety and Efficacy of Pirfenidone in the Treatment of Idiopathic Pulmonary Fibrosis (IPF)Idiopathic Pulmonary FibrosisDrug: Pirfenidone;Drug: PlaceboBeijing Kawin Technology Share-Holding Co., Ltd.Recruiting18 Years75 YearsBoth80Phase 2China
160NCT02136992December 201119 February 2015Clinical Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary FibrosisA Multicenter, Randomized, Double-blind, Placebo-controlled Trial for Clinical Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary FibrosisIdiopathic Pulmonary FibrosisDrug: Pirfenidone;Drug: placeboShanghai Pulmonary Hospital, Shanghai, ChinaNanjing Chia-tai Tianqing PharmaceuticalNot recruitingN/A75 YearsBoth160Phase 2
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
161NCT01382368September 201119 February 2015Acute Effect of Sildenafil on Exercise Tolerance and Functional Capacity in COPD, IPF and Post Pneumonectomy PatientsAcute Effect of Sildenafil on Exercise Tolerance and Functional Capacity in COPD, IPF and Post Pneumonectomy PatientsChronic Obstructive Pulmonary Disease;Idiopathic Pulmonary FibrosisDrug: SildenafilRabin Medical CenterRecruiting30 Years90 YearsBoth60Phase 4Israel
162NCT01417156September 201116 December 2017Safety and PK Study of BIBF 1120 in Japanese Patients With IPF: Follow up Study From 1199.31(NCT01136174)A Phase II Open Label, Follow up Study to Investigate the Long Term Tolerability and Safety of Oral BIBF 1120 on Top of Pirfenidone in Japanese Patients With Idiopathic Pulmonary FibrosisPulmonary FibrosisDrug: Nintedanib;Drug: PirfenidoneoneBoehringer IngelheimNot recruiting40 YearsN/AAll20Phase 2Japan
163NCT01432080September 201116 December 2017Steroids, Azithromycin, Montelukast, and Symbicort (SAMS) for Viral Respiratory Tract Infection Post AllotransplantDoes Increasing Immunosuppression Prevent Transplant-associated Lung-disease Triggered by Viral Respiratory Tract Infection Following Allogeneic Stem Cell Transplant? A Pilot StudyRespiratory Tract Infections;Bronchiolitis Obliterans;Cryptogenic Organizing Pneumonia;Lung Diseases, InterstitialDrug: Prednisone;Drug: Azithromycin;Drug: Montelukast;Drug: SymbicortMaisonneuve-Rosemont HospitalThe Canadian Blood and Marrow Transplant GroupNot recruiting18 YearsN/AAll12Phase 2Canada
164NCT01214187July 201116 December 2017Study of Inhaled Carbon Monoxide to Treat Idiopathic Pulmonary FibrosisPhase II Study of Inhaled CO for the Treatment of Idiopathic Pulmonary FibrosisIdiopathic Pulmonary FibrosisDrug: inhaled carbon monoxide;Other: OxygenBrigham and Women's HospitalNational Heart, Lung, and Blood Institute (NHLBI);University of California, San Francisco;University of Chicago;University of Illinois at Chicago;University of Michigan;Columbia University;Tulane University;University of WashingtonNot recruiting18 Years85 YearsAll58Phase 2United States
165NCT01346930July 201119 February 2015Safety and Tolerability Study of Macitentan in Patients With Idiopathic Pulmonary FibrosisLong Term, Single-arm, Open-label Extension Study of the MUSIC Study to Assess the Safety and Tolerability of Macitentan in Patients With Idiopathic Pulmonary FibrosisIdiopathic Pulmonary FibrosisDrug: MacitentanActelionNot recruiting18 YearsN/ABoth0Phase 2
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
166EUCTR2010-023828-24-GB09/06/201127 May 2013The effect of Thalidomide on sputum biomarkers in IPF cough. - The effect of Thalidomide on sputum biomarkers in IPF coughThe effect of Thalidomide on sputum biomarkers in IPF cough. - The effect of Thalidomide on sputum biomarkers in IPF coughCough in Idiopathic Pulmonary fibrosis.Trade Name: Thalidomide Pharmion
Product Name: Thalidomide Pharmion
Pharmaceutical Form: Capsule
Trade Name: PREDNISOLONE
Product Name: prednisolone
Pharmaceutical Form: Tablet
University of NottinghamNot RecruitingFemale: yes
Male: yes
United Kingdom
167NCT01366209June 201116 December 2017Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF)A Randomized, Double-Blind, Placebo Controlled, Phase 3 Study of the Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (ASCEND Trial)Idiopathic Pulmonary FibrosisDrug: Pirfenidone;Drug: PlaceboGenentech, Inc.Not recruiting40 Years80 YearsAll555Phase 3United States
168EUCTR2010-024211-13-SE26/05/201119 March 2012Study to evaluate if macitentan is safe and tolerable enough to be used for treatment of idiopathic pulmonary fibrosis, following the MUSIC studyLong term, single-arm, open-label extension study of the MUSIC study to assess the safety and tolerability of macitentan in patients with idiopathic pulmonary fibrosis - MUSIC OLPatients with Idiopathic Pulmonary Fibrosis
MedDRA version: 13.1 Level: PT Classification code 10021240 Term: Idiopathic pulmonary fibrosis System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders ;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
Product Name: Macitentan
Product Code: ACT-064992
Pharmaceutical Form: Film-coated tablet
INN or Proposed INN: macitentan
CAS Number: 441798-33-0
Current Sponsor code: ACT-064992
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 10-
ACTELION Pharmaceuticals Ltd.AuthorisedFemale: yes
Male: yes
178Germany;Canada;Turkey;Spain;United States;South Africa;Australia;Sweden;Israel
169EUCTR2010-024251-87-DE12/04/20113 February 2014Safety and Efficacy of BIBF 1120 at high dose in Idiopathic Pulmonary Fibrosis patientsA 52 weeks, double blind, randomized, placebo-controlled trial evaluating the effect of oral BIBF 1120, 150 mg twice daily, on annual Forced Vital Capacity decline , in patients with Idiopathic Pulmonary Fibrosis (IPF)Idiopathic Pulmonary Fibrosis
MedDRA version: 14.1 Level: PT Classification code 10021240 Term: Idiopathic pulmonary fibrosis System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders ;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
Product Name: BIBF 1120
Product Code: BIBF 1120
Pharmaceutical Form: Capsule, soft
Current Sponsor code: BIBF 1120
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 150-
Pharmaceutical form of the placebo: Capsule, soft
Route of administration of the placebo: Oral use
Product Name: BIBF 1120
Product Code: BIBF 1120
Pharmaceutical Form: Capsule, soft
Current Sponsor code: BIBF 1120
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 100-
Pharmaceutical form of the placebo: Capsule, soft
Route of administration of the placebo: Oral use
Boehringer Ingelheim Pharma GmbH & Co. KGNot RecruitingFemale: yes
Male: yes
485United States;Ireland;Israel;Italy;United Kingdom;India;France;Czech Republic;Argentina;Belgium;Brazil;Australia;Germany;Japan;China
170EUCTR2010-024252-29-FI01/04/201116 December 2013A 52 weeks, double blind, randomized, placebo-controlled trial evaluating the effect of oral BIBF 1120, 150 mg twice daily, on Forced Vital Capacity decline , in patients with Idiopathic Pulmonary Fibrosis (IPF)A 52 weeks, double blind, randomized, placebo-controlled trial evaluating the effect of oral BIBF 1120, 150 mg twice daily, on Forced Vital Capacity decline , in patients with Idiopathic Pulmonary Fibrosis (IPF)Idiopathic Pulmonary Fibrosis
MedDRA version: 12.1 Level: PT Classification code 10021240 Term: Idiopathic pulmonary fibrosis
Product Name: BIBF 1120
Product Code: BIBF 1120
Pharmaceutical Form: Capsule, soft
Current Sponsor code: BIBF 1120
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 150-
Pharmaceutical form of the placebo: Capsule, soft
Route of administration of the placebo: Oral use
Product Name: BIBF 1120
Product Code: BIBF 1120
Pharmaceutical Form: Capsule, soft
Current Sponsor code: BIBF 1120
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 100-
Pharmaceutical form of the placebo: Capsule, soft
Route of administration of the placebo: Oral use
Boehringer IngelheimNot RecruitingFemale: yes
Male: yes
485Portugal;Greece;Finland;Spain;Netherlands;Germany
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
171NCT01262001March 201114 October 2019Safety, Tolerability, and Efficacy Study of Idiopathic Pulmonary FibrosisA Phase 2, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Efficacy of FG-3019 in Subjects With Idiopathic Pulmonary FibrosisIdiopathic Pulmonary FibrosisDrug: FG-3019FibroGenNot recruiting35 Years80 YearsAll90Phase 2United States
172NCT01265888March 201126 September 2016Study in Subjects With PAH and PH Secondary to IPF Using Inhaled GeNOsyl.A Phase 2, Open-Label, Dose-Escalation Study in Subjects With Pulmonary Arterial Hypertension, (PAH, WHO Group 1) and Pulmonary Hypertension Secondary to Idiopathic Pulmonary Fibrosis, (PH-IPF WHO Group 3) Using Inhaled GeNOsyl.Pulmonary Arterial Hypertension;Idiopathic Pulmonary FibrosisDrug: Inhaled Nitric OxideGeno LLCNot recruiting18 Years80 YearsBoth31Phase 2United States
173NCT01266317March 201118 January 2016Combined PEX, Rituximab and Steroids in Acute IPF ExacerbationsOpen-Label, Feasibility Study of Combined Plasma Exchange (PEX), Rituximab, and Corticosteroids in Patients With Acute Idiopathic Pulmonary Fibrosis ExacerbationsIPFDrug: Combined Plasma Exchange (PEX), Rituximab, and CorticosteroidsUniversity of PittsburghNot recruiting18 Years80 YearsBoth10Phase 1/Phase 2United States
174ChiCTR-TRC-120023722011-02-2318 April 2017Levofloxacin (Cravit) versus Moxifloxacin-concentration of epithelial lining fluid in patients with idiopathic pulmonary fibrosis (IPF)Levofloxacin (Cravit) versus Moxifloxacin-concentration of epithelial lining fluid in patients with idiopathic pulmonary fibrosisidiopathic pulmonary fibrosisCravit IPF Group:Cravit 500 mg per time;Cravit Normal Pulmonary Function Group:Cravit 500 mg per time;Moxifloxacin IPF Group:Moxifloxacin 400mg per time;Moxifloxacin Normal PulmonaryFunction Group:Moxifloxacin 400mg per time;Respiratory Department, Peking Union Medical College HospitalNot Recruiting1870BothCravit IPF Group:12;Cravit Normal Pulmonary Function Group:12;Moxifloxacin IPF Group:12;Moxifloxacin Normal PulmonaryFunction Group:12;OtherChina
175JPRN-UMIN0000050982011/02/012 April 2019A randomized trial of ambulatory oxygen in patients with idiopathic pulmonary fibrosis and desaturation but without resting hypoxemiaidiopathic pulmonary fibrosisambulatory oxygen
ambulatory air
Department of Respiratory Medicine and Allergology, Kinki University School of MedicineNot Recruiting20years-oldNot applicableMale and Female20Not selectedJapan
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
176JPRN-UMIN0000047492011/01/012 April 2019A study to evaluate the long-term effect of pulmonary hypertension on prognosis, activities of daily living (ADL), cardiac function and pulmonary function in patients with COPD and idiopathic pulmonary fibrosis (IPF), respectively, according to baseline severity of pulmonary hypertension and the efficacy and safety of the Tracleer (bosentan hydrate) tablet for prognosis, activities of daily living, cardiac function and pulmonary function in patients with COPD and IPF, respectively, according to baseline severity of pulmonary hypertension.Patients with COPD or IPF (WHO functional class II, III or IV), without hypoxia (PaO2 at rest<90mmHg or after 6minutes walk), who provide their informed consent to participate in this study.Treated subgroup
In patients with COPD without hypoxia (PaO2<60mmHg at rest or after 6 minutes walk) (WHO functional class II, III or IV), patients with Pulmonary hypertension with evidense of mPAP at rest=/>35mmHg : 20subjects
Bosentan will be administered basically according to the approved dosage and administration, as specified below. However, in this study conducted in accordance with routine clinical practice, the initial dosage may be used continuously if considered appropriate based on the patient's condition.
Treatment with bosentan in adults is usually initiated at a dose of 62.5 mg twice daily to be taken orally after breakfast and the evening meal for 4 weeks. From Week 5 of treatment, bosentan is administered at a dose of 125 mg twice daily to be taken orally after breakfast and evening meal. The dosage should be adjusted according to the patient's symptoms and tolerability, but should not exceed 250 mg per day.
Duration of study drug administration: 24 months

In addition, Interventions/Control 11 and 12 is described in Interventions/control 10.
Treated subgroup
In patients with COPD without hypoxia (PaO2<60mmHg at rest or after 6 minutes walk) (WHO functional class II, III or IV), patients with boarderline pulmonary hypertension or pulmonary hypertension (mPAP at rest=/>25mmHg and/or mPAP on effort=/>30mmHg) with mPAP at rest<35mmHg: 20subjects
Tracleer Tablets will be administered basically according to the approved dosage and administration, as specified below. However, in this study conducted in accordance with routine clinical practice, the initial dosage may be used continuously if considered appropriate based on the patient's condition.
Treatment with bosentan in adults is usually initiated at a dose of 62.5 mg twice daily to be taken orally after breakfast and the evening meal for 4 weeks. From Week 5 of treatment, bosentan is administered at a dose of 125 mg twice daily to be taken orally after breakfast and even
Department of Respiratory Medicine, Chiba-Hokusoh Hospital, Nippon Medical SchoolRecruiting40years-oldNot applicableMale and Female160Not applicableJapan
177NCT01203943January 201119 February 2015A Study to Characterize the Safety, PK and Biological Activity of CC-930 in Idiopathic Pulmonary Fibrosis (IPF)A Phase 2 Sequential, Ascending Dose Study to Characterize the Safety, Tolerability, Pharmacokinetic and Biological Activity of CC-930 in Idiopathic Pulmonary Fibrosis (IPF)Idiopathic Pulmonary Fibrosis;Pulmonary Fibrosis;Fibrosis;Interstitial Lung Disease;Lung Diseases, InterstitialDrug: CC-930;Other: PlaceboCelgene CorporationNot recruiting50 YearsN/ABoth28Phase 2United States;Canada
178NCT01254409January 201119 October 2017A Phase 1b Study of IV PRM151 in Patients With Idiopathic Pulmonary Fibrosis (IPF)A Randomized, Double-Masked, Sponsor-Unmasked, Ascending Multiple Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PRM-151 Administered Intravenously to Patients With Idiopathic Pulmonary FibrosisIdiopathic Pulmonary FibrosisBiological: PRM-151;Other: PlaceboPromedior, Inc.Not recruiting40 Years80 YearsAll21Phase 1United States;Netherlands
179NCT01280994January 201123 April 2019Hyperpolarized 129Xe MRI for Imaging Pulmonary FunctionHyperpolarized 129Xe MR Imaging of the Lung Function in Healthy Volunteers and Subjects With Pulmonary DiseaseInterstitial Lung Disease;Cystic Fibrosis;Pulmonary Hypertension;NSIP;Alpha 1-Antitrypsin DeficiencyDrug: XenonBastiaan DriehuysRecruiting18 Years80 YearsAll445Phase 1United States
180NCT01266135December 201028 April 2015Safety and Efficacy of QAX576 in Patients With Idiopathic Pulmonary Fibrosis (IPF)Randomized, Double-blind, Placebo-controlled, Multiple-dose, Exploratory Proof of Concept Study to Assess the Safety, Tolerability, Efficacy, Pharmacodynamic (PD) and Pharmacokinetics of QAX576 in Patients With Rapidly Progressive IPFIdiopathic Pulmonary FibrosisDrug: QAX576;Drug: PlaceboNovartis PharmaceuticalsNot recruiting18 Years80 YearsBoth40Phase 2United States;United Kingdom
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
181NCT01362231December 20103 August 2015A Study to Evaluate the Safety and Efficacy of GS-6624 (Formerly AB0024) in Patients With Idiopathic Pulmonary FibrosisA Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-6624 in Adult Subjects With Idiopathic Pulmonary FibrosisIdiopathic Pulmonary FibrosisDrug: GS-6624Gilead SciencesNot recruiting40 Years85 YearsBoth48Phase 1United States
182EUCTR2008-004405-34-CZ13/09/201018 April 2012A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group, Event-Driven Study to Evaluate the Efficacy and Safety of Ambrisentan in Subjects with Early Idiopathic Pulmonary Fibrosis (IPF) - ARTEMIS-IPFA Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group, Event-Driven Study to Evaluate the Efficacy and Safety of Ambrisentan in Subjects with Early Idiopathic Pulmonary Fibrosis (IPF) - ARTEMIS-IPFIdiopathic pulmonary fibrosis (IPF)
MedDRA version: 9.1 Level: LLT Classification code 10021240 Term: Idiopathic pulmonary fibrosis
Trade Name: Letairis 5 mg
Pharmaceutical Form: Film-coated tablet
INN or Proposed INN: Ambrisentan
CAS Number: 177036-94-1
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 5-
Pharmaceutical form of the placebo: Film-coated tablet
Route of administration of the placebo: Oral use
Trade Name: Letairis 10 mg
Pharmaceutical Form: Film-coated tablet
INN or Proposed INN: Ambrisentan
CAS Number: 177036-94-1
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 10-
Pharmaceutical form of the placebo: Film-coated tablet
Route of administration of the placebo: Oral use
Gilead Sciences IncorporatedNot RecruitingFemale: yes
Male: yes
660Phase 3United Kingdom;Germany;Czech Republic;Netherlands;Belgium;France;Spain;Ireland;Italy;Austria
183NCT01199887September 201019 February 2015Trial Of IW001 in Patients With Idiopathic Pulmonary FibrosisA Phase One, Open Label, Multi-Dose Study to Evaluate the Safety, Tolerability, and Biologic Effects of Three Doses of IW001 in Patients With Idiopathic Pulmonary Fibrosis (IPF)Idiopathic Pulmonary FibrosisDrug: IW001ImmuneWorksNot recruiting35 Years75 YearsBoth30Phase 1United States
184EUCTR2010-020223-44-AT03/08/201019 March 2012(18)F-FDG PET/CT in patients with idiopathic interstitial pneumonias: correlation of tracer uptake and histological findings, and texture-based recognition of usual interstitial pneumonia(18)F-FDG PET/CT in patients with idiopathic interstitial pneumonias: correlation of tracer uptake and histological findings, and texture-based recognition of usual interstitial pneumoniaInterstitial lung disease of unknown etiologyTrade Name: (18)F-FDG
Product Name: (18)F-FDG
Pharmaceutical Form: Solution for injection
INN or Proposed INN: FLUORINE (18F) FLUDEOXYGLUCOSE
CAS Number: 105851-17-0
Concentration unit: MBq megabecquerel(s)
Concentration type: equal
Concentration number: 300 MBq-
Medizinische Universität Wien, Univ.Klinik f.RadiodiagnostikAuthorisedFemale: yes
Male: yes
Austria
185NCT01135199June 201020 April 2015Pomalidomide for Cough in Patients With Idiopathic Pulmonary FibrosisSafety and Efficacy of Pomalidomide in the Treatment of Refractory Cough in Patients With Idiopathic Pulmonary Fibrosis (IPF): A Pilot StudyPulmonary FibrosisDrug: pomalidomide (CC-4047Stanford UniversityCelgene CorporationNot recruiting18 YearsN/ABoth0Phase 2United States
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
186NCT01136174May 201019 October 2017Safety and PK Study of BIBF 1120 in Japanese Patients With IPFA Double-blind, Randomised, Placebo-controlled (Within a Dose Group) Study to Evaluate Safety and Pharmacokinetics of Multiple Rising Doses of BIBF 1120 at 50 mg Bid (14 Days), 100 mg Bid (14 Days), and 150 mg Bid (28 Days) p.o., on Top of Standard Medical Care With Stratification According to Pirfenidone Use, in Japanese Patients With Idiopathic Pulmonary Fibrosis.Idiopathic Pulmonary FibrosisDrug: Placebo;Drug: BIBF 1120Boehringer IngelheimNot recruiting40 YearsN/AAll50Phase 2Japan
187EUCTR2009-013788-21-ES28/04/201019 October 2015Ensayo clínico de Fase II, abierto, y de extensión para evaluar la tolerabilidad a largo plazo, la seguridad y la eficacia de BIBF 1120 administrado por vía oral en pacientes con Fibrosis Pulmonar Idiopática A phase II open label, roll over study of the long term tolerability, safety and efficacy of oral BIBF 1120 in patients with Idiopathic Pulmonary FibrosisEnsayo clínico de Fase II, abierto, y de extensión para evaluar la tolerabilidad a largo plazo, la seguridad y la eficacia de BIBF 1120 administrado por vía oral en pacientes con Fibrosis Pulmonar Idiopática A phase II open label, roll over study of the long term tolerability, safety and efficacy of oral BIBF 1120 in patients with Idiopathic Pulmonary FibrosisFibrosis Pulmonar Idiopática
MedDRA version: 12.1 Level: PT Classification code 10021240 Term: Idiopathic pulmonary fibrosis
Product Name: BIBF 1120
Product Code: BIBF 1120
Pharmaceutical Form: Capsule, soft
Current Sponsor code: BIBF 1120
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 50-
Product Name: BIBF 1120
Product Code: BIBF 1120
Pharmaceutical Form: Capsule, soft
Current Sponsor code: BIBF 1120
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 100-
Product Name: BIBF 1120
Product Code: BIBF 1120
Pharmaceutical Form: Capsule, soft
Current Sponsor code: BIBF 1120
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 150-
Boehringer Ingelheim España S.A.Not RecruitingFemale: yes
Male: yes
300Phase 2Portugal;France;Czech Republic;Hungary;Greece;Belgium;Spain;Ireland;Bulgaria;Germany;United Kingdom;Italy
188EUCTR2009-013788-21-BE22/04/201028 November 2016A phase II open label, roll over study of the long term tolerability, safety and efficacy of oral BIBF 1120 in patients with Idiopathic Pulmonary FibrosisA phase II open label, roll over study of the long term tolerability, safety and efficacy of oral BIBF 1120 in patients with Idiopathic Pulmonary FibrosisIdiopathic Pulmonary Fibrosis
MedDRA version: 17.0 Level: PT Classification code 10021240 Term: Idiopathic pulmonary fibrosis System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders
Product Name: BIBF 1120
Product Code: BIBF 1120
Pharmaceutical Form: Capsule, soft
Current Sponsor code: BIBF 1120
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 50-
Product Name: BIBF 1120
Product Code: BIBF 1120
Pharmaceutical Form: Capsule, soft
Current Sponsor code: BIBF 1120
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 100-
Product Name: BIBF 1120
Product Code: BIBF 1120
Pharmaceutical Form: Capsule, soft
Current Sponsor code: BIBF 1120
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 150-
SCS Boehringer Ingelheim Comm.VNot RecruitingFemale: yes
Male: yes
300Phase 2Portugal;France;Czech Republic;Hungary;Greece;Spain;Belgium;Ireland;Bulgaria;Germany;United Kingdom;Italy
189EUCTR2009-011169-98-DE03/11/200919 March 2012ARTEMIS-PH: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group Study to Evaluate the Efficacy and Safety of Ambrisentan in Subjects with Idiopathic Pulmonary Fibrosis and Pulmonary Hypertension - ARTEMIS-PHARTEMIS-PH: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group Study to Evaluate the Efficacy and Safety of Ambrisentan in Subjects with Idiopathic Pulmonary Fibrosis and Pulmonary Hypertension - ARTEMIS-PHPulmonary Hypertension associated with Idiopathic Pulmonary Fibrosis
MedDRA version: 12.0 Level: LLT Classification code 10021240 Term: Idiopathic pulmonary fibrosis
MedDRA version: 12.0 Level: LLT Classification code 10037400 Term: Pulmonary hypertension
Trade Name: Letairis
Pharmaceutical Form: Film-coated tablet
INN or Proposed INN: Ambrisentan
CAS Number: 177036-94-1
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 5-
Pharmaceutical form of the placebo: Film-coated tablet
Route of administration of the placebo: Oral use
Trade Name: Letairis
Pharmaceutical Form: Film-coated tablet
INN or Proposed INN: Ambrisentan
CAS Number: 177036-94-1
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 10-
Pharmaceutical form of the placebo: Film-coated tablet
Route of administration of the placebo: Oral use
Gilead Sciences, IncNot RecruitingFemale: yes
Male: yes
225Phase 3Czech Republic;United Kingdom;Germany;Italy;Austria
190JPRN-UMIN0000057932009/11/012 April 2019Open-label study of tiotropium/pirfenidone for idiopathic pulmonary fibrosis with emphysemaIdiopathic pulmonary fibrosis (IPF) with centrilobular emphysema (CLE)tiotropium for 8 weeks and then
tiotropium + pirfenidone for 44 weeks
pirfenidone 44 weeks and then
tiotropium + pirfenidone for 8 weeks
Saitama Medical UniversityRecruiting40years-oldNot applicableMale and Female60Not selectedJapan
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
191JPRN-UMIN0000160452009/10/0321 May 2019A case-control study evaluating the efficacy and safety of combined therapy with pirfenidone and inhaled N-acetylcysteine for idiopathic pulmonary fibrosis.A case-control study evaluating the efficacy and safety of combined therapy with pirfenidone and inhaled N-acetylcysteine for idiopathic pulmonary fibrosis. - Combined therapy with pirfenidone and inhaled N-acetylcysteine for idiopathic pulmonary fibrosis.Idiopathic pulmonary fibrosisUsing Micro Air nebulizers and vibration mesh technology (NE-U07, Omron, Tokyo, Japan), patients receiving NAC combined with pirfenidone were treated twice daily with 352.4 mg of inhaled NAC, which was diluted with saline to a total volume of 6 mL for 48 weeks.
Pirfenidone 1200-1800mg (control group)
Department of Respiratory Medicine, Toho University Omori Medical Center, Tokyo,Not Recruiting20years-oldNot applicableMale and Female20Not selectedJapan
192NCT00957242October 200919 October 2017AntiCoagulant Effectiveness in Idiopathic Pulmonary FibrosisAntiCoagulant Effectiveness in Idiopathic Pulmonary Fibrosis (ACE-IPF)Idiopathic Pulmonary FibrosisDrug: warfarin;Drug: placeboDuke UniversityNational Heart, Lung, and Blood Institute (NHLBI);Duke Clinical Research InstituteNot recruiting35 Years80 YearsAll145Phase 3United States
193NCT00981747September 200916 December 2017Targeting Vascular Reactivity in Idiopathic Pulmonary FibrosisA Clinical Treatment Trial Targeting Vascular Reactivity in Idiopathic Pulmonary FibrosisIdiopathic Pulmonary Fibrosis;Pulmonary FibrosisDrug: Sildenafil;Drug: Losartan;Drug: Sildenafil and Losartan;Drug: Placebo pillUniversity of IowaPulmonary Fibrosis FoundationNot recruiting18 Years99 YearsAll16Phase 2/Phase 3United States
194NCT00879229July 200919 October 2017ARTEMIS-PH - Study of Ambrisentan in Subjects With Pulmonary Hypertension Associated With Idiopathic Pulmonary FibrosisA Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group Study to Evaluate the Efficacy and Safety of Ambrisentan in Subjects With Idiopathic Pulmonary Fibrosis and Pulmonary HypertensionIdiopathic Pulmonary Fibrosis;Pulmonary HypertensionDrug: Ambrisentan;Drug: PlaceboGilead SciencesNot recruiting35 Years80 YearsAll40Phase 3United States;Australia;Austria;Canada;Germany;Italy;United Kingdom;Belgium;Ireland;Israel
195NCT00903331May 200919 October 2017Macitentan Use in an Idiopathic Pulmonary Fibrosis Clinical StudyA Double-blind, Randomized, Placebo-controlled, Multicenter, Parallel Group Study to Evaluate the Efficacy, Safety, and Tolerability of Macitentan in Patients With Idiopathic Pulmonary FibrosisIdiopathic Pulmonary FibrosisDrug: ACT-064992 (macitentan);Drug: PlaceboActelionNot recruiting18 YearsN/AAll178Phase 2United States;Australia;Canada;France;Germany;Israel;Italy;Slovenia;South Africa;Spain;Sweden;Turkey
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
196NCT00879879March 200919 October 2017Losartan in Treating Patients With Idiopathic Pulmonary FibrosisTreatment of Idiopathic Pulmonary Fibrosis With Losartan: A Pilot ProjectPrecancerous ConditionDrug: losartanUniversity of South FloridaNational Cancer Institute (NCI)Not recruiting21 YearsN/AAll20N/AUnited States
197EUCTR2008-007168-40-IT20/01/200919 March 2012Use of 68Ga-DOTA-NOC for the evaluation of patients with Idiopathic pulmonary fibrosis STUDY CODE: 68Ga-DOTA-NOC/ILD 01/2008 - 68Ga-DOTA-NOC/ILD01/2008Use of 68Ga-DOTA-NOC for the evaluation of patients with Idiopathic pulmonary fibrosis STUDY CODE: 68Ga-DOTA-NOC/ILD 01/2008 - 68Ga-DOTA-NOC/ILD01/2008patients with Idiopathic pulmonary fibrosis
MedDRA version: 9.1 Level: LLT Classification code 10021240 Term: Idiopathic pulmonary fibrosis
Product Name: Gallium68-Dota-Noc
Pharmaceutical Form: Solution for injection
Concentration unit: MBq megabecquerel(s)
Concentration type: equal
Concentration number: 185-
AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHIAuthorisedFemale: yes
Male: yes
Italy
198EUCTR2008-001281-86-NL14/01/200919 March 2012A Phase 2, Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Evaluating the Efficacy and Safety of CNTO 888 Administered Intravenously in Subjects with Idiopathic Pulmonary FibrosisA Phase 2, Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Evaluating the Efficacy and Safety of CNTO 888 Administered Intravenously in Subjects with Idiopathic Pulmonary FibrosisIdiopathic pulmonary fibrosis (IPF)
MedDRA version: 9.1 Level: LLT Classification code 10021240 Term: Idiopathic pulmonary fibrosis
Product Name: CNTO888
Product Code: CNTO888
Pharmaceutical Form: Powder for solution for infusion
Current Sponsor code: CNTO888
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 50-
Pharmaceutical form of the placebo: Solution for infusion
Route of administration of the placebo: Intravenous use
Centocor B.V.Not RecruitingFemale: yes
Male: yes
120Phase 2Germany;Netherlands;Belgium
199JPRN-UMIN0000252562009/01/012 April 2019Benefits of supplemental oxygen on exercise capacity and dyspnea in IPF patientsidiopathic pulmonary fibrosisoxygen gas
air gas
Tosei General HospitalNot RecruitingNot applicable75years-oldMale and Female106Not applicableJapan
200NCT00768300December 200819 October 2017(ARTEMIS-IPF) Randomized, Placebo-Controlled Study to Evaluate Safety and Effectiveness of Ambrisentan in IPFARTEMIS-IPF: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group, Event Driven Study to Evaluate the Efficacy and Safety of Ambrisentan in Subjects With Early Idiopathic Pulmonary Fibrosis (IPF)Idiopathic Pulmonary FibrosisDrug: Ambrisentan;Drug: PlaceboGilead SciencesNot recruiting40 Years80 YearsAll494Phase 3United States;Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;Colombia;Czech Republic;France;Germany;Ireland;Israel;Italy;Mexico;Netherlands;Peru;Poland;Spain;Switzerland;United Kingdom
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
201NCT00786201December 200819 February 2015A Study to Evaluate the Safety and Effectiveness of CNTO 888 Administered Intravenously (IV) in Participants With Idiopathic Pulmonary Fibrosis (IPF)A Phase 2, Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Evaluating the Efficacy and Safety of CNTO 888 Administered Intravenously in Subjects With Idiopathic Pulmonary FibrosisPulmonary FibrosisDrug: Placebo;Drug: CNTO 888 1 mg/kg;Drug: CNTO 888 5 mg/kg;Drug: CNTO 888 15 mg/kgCentocor, Inc.Not recruiting40 Years80 YearsBoth126Phase 2United States;Belgium;Canada;Germany;Netherlands
202JPRN-UMIN0000135592008/10/012 April 2019A prospective and multicenter trial of intravenous immunoglobulin therapy for idiopathic pulmonary fibrosisIdiopathic pulmonary fibrosisPatients were treated with intravenous immunoglobulin (IVIG) at 0.4 g/kg/day for 5 consecutive days (5-day IVIG group)
Patients were treated with intravenous immunoglobulin (IVIG) at 0.4 g/kg/day once-monthly for 5 consecutive months (5-month IVIG group)
Second Division, Department of Internal Medicine, Hamamatsu University School of MedicineNot Recruiting50years-old75years-oldMale and Female10Not applicableJapan
203NCT00662038August 200816 December 2017Open-Label Study of the Long Term Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF)An Open-Label Extension Study of the Long Term Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF)Idiopathic Pulmonary FibrosisDrug: pirfenidoneGenentech, Inc.Hoffmann-La RocheNot recruiting40 Years84 YearsAll1058Phase 3United States
204NCT00705133July 200811 June 2018Treprostinil Therapy For Patients With Interstitial Lung Disease And Severe Pulmonary Arterial HypertensionUsing Either Intravenous (IV) or Subcutaneous (SQ) Treprostinil to Treat Pulmonary Hypertension Related to Underlying Interstitial Lung DiseasePulmonary Arterial Hypertension;Interstitial Lung Disease;Idiopathic Pulmonary FibrosisDrug: TreprostinilRajan SaggarUnited TherapeuticsNot recruitingN/AN/AAll15Phase 2United States
205EUCTR2007-001741-18-FR24/06/200818 April 2012Open-label extension study in patients with Idiopathic Pulmonary Fibrosis who completed protocol AC-052-321 / BUILD 3 - BUILD-3-OLOpen-label extension study in patients with Idiopathic Pulmonary Fibrosis who completed protocol AC-052-321 / BUILD 3 - BUILD-3-OLIdiopathic Pulmonary Fibrosis (IPF)
MedDRA version: 9.1 Level: LLT Classification code 10021240 Term: Idiopathic pulmonary fibrosis
Trade Name: Tracleer
Product Name: Bosentan
Product Code: Ro 47-0203
Pharmaceutical Form: Film-coated tablet
INN or Proposed INN: BOSENTAN
CAS Number: 147536978
Current Sponsor code: Ro 47-0203
Other descriptive name: Tracleer
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 62.5-
Trade Name: Tracleer
Product Name: Bosentan
Product Code: Ro 47-0203
Pharmaceutical Form: Film-coated tablet
INN or Proposed INN: BOSENTAN
CAS Number: 147536978
Current Sponsor code: Ro 47-0203
Other descriptive name: Tracleer
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 125-
Actelion Pharmaceuticals LtdAuthorisedFemale: yes
Male: yes
390Germany;Czech Republic;United Kingdom;Netherlands;Belgium;France;Ireland;Spain;Italy;Austria
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
206EUCTR2007-007800-13-IE04/06/200823 January 2017An Open-Label Extension Study of the Long-Term Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (IPF) Who Complete the CAPACITY Studies - Open-Label Extension of Pirfenidone CAPACITY StudiesAn Open-Label Extension Study of the Long-Term Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (IPF) Who Complete the CAPACITY Studies - Open-Label Extension of Pirfenidone CAPACITY StudiesIdiopathic Pulmonary Fibrosis (IPF)
MedDRA version: 9.1 Level: LLT Classification code 10021240 Term: Idiopathic pulmonary fibrosis
Product Name: Pirfenidone
Pharmaceutical Form: Capsule, hard
INN or Proposed INN: Pirfenidone
Current Sponsor code: 53179-13-8
Other descriptive name: PIR, S-7701
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 267-
InterMune, Inc.Not RecruitingFemale: yes
Male: yes
750Phase 3France;Belgium;Germany;Italy;United Kingdom;Ireland;Spain
207NCT00690885June 200819 February 2015Interferon-alpha Treatment of Chronic Cough in Chronic Obstructive Pulmonary Disease and Idiopathic Pulmonary FibrosisEvaluation of Natural Human Interferon Alpha Lozenges in the Treatment of Chronic Cough in Patients With Chronic Obstructive Pulmonary Disease (COPD) or Idiopathic Pulmonary Fibrosis (IPF)Pulmonary Disease, Chronic Obstructive;Pulmonary Fibrosis;CoughDrug: interferon-alpha lozenges;Drug: placebo lozengesAmarillo Biosciences, Inc.Texas Tech University Health Sciences CenterNot recruiting40 YearsN/ABoth1Phase 2United States
208NCT00703339June 200811 June 2018Effects of Inhaled Treprostinil Sodium for the Treatment of Pulmonary Hypertension Associated With Idiopathic Pulmonary FibrosisA Single-Dose, Dose-Escalating Study Exploring the Safety, Pharmacokinetics, and Pharmacodynamic Effects of Inhaled Treprostinil Sodium Using the Nebu-Tec OPTINEB Inhalation Device in Patients With Pulmonary Hypertension Associated With Idiopathic Pulmonary FibrosisIdiopathic Pulmonary Fibrosis;Pulmonary HypertensionDrug: Treprostinil sodium for inhalationLung Biotechnology PBCNot recruiting35 Years80 YearsAll1Phase 2United States
209NCT00631475April 200819 October 2017Open Label Extension Study in Patients With Idiopathic Pulmonary Fibrosis Who Completed Protocol AC-052-321/ BUILD 3 / NCT00391443Open-Label Extension Study in Patients With Idiopathic Pulmonary Fibrosis Who Completed Protocol AC-052-321 (NCT00391443)Idiopathic Pulmonary FibrosisDrug: BosentanActelionNot recruiting18 YearsN/AAll128Phase 3United States;Australia;Belgium;Canada;Czech Republic;France;Germany;Ireland;Israel;Italy;Japan;Korea, Republic of;Spain;Switzerland;United Kingdom;Austria;Croatia;Former Serbia and Montenegro;Netherlands;Serbia
210EUCTR2008-006054-17-DE22 October 2012A double-blind, randomized, placebo-controlled, multicenter, parallel group study to evaluate the efficacy, safety, and tolerability of macitentan in patients with idiopathic pulmonary fibrosis - MUSICA double-blind, randomized, placebo-controlled, multicenter, parallel group study to evaluate the efficacy, safety, and tolerability of macitentan in patients with idiopathic pulmonary fibrosis - MUSICTo evaluate the efficacy, safety, and tolerabilitiy of macitentan in patients with idiopathic pulmonary fibrosis.
MedDRA version: 9.1 Level: LLT Classification code 10021240 Term: Idiopathic pulmonary fibrosis
Product Name: macitentan
Product Code: ACT-064992
Pharmaceutical Form: Tablet
INN or Proposed INN: macitentan
CAS Number: 441798-33-0
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 10-
Pharmaceutical form of the placebo: Tablet
Route of administration of the placebo: Oral use
Actelion Pharmaceuticals Ltd.Not RecruitingFemale: yes
Male: yes
156France;Slovenia;Spain;Germany;Italy;Sweden
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
211EUCTR2007-001645-17-GB04/12/200719 March 2012Prevention of Established Pulmonary Hypertension in High Risk patients with Fibrotic Lung Disease – a double-blinded, randomised, placebo controlled trial with endothelin-1 receptor antagonist therapy - Prevention of Pulmonary Hypertension in Interstitial Lung DiseasePrevention of Established Pulmonary Hypertension in High Risk patients with Fibrotic Lung Disease – a double-blinded, randomised, placebo controlled trial with endothelin-1 receptor antagonist therapy - Prevention of Pulmonary Hypertension in Interstitial Lung DiseasePulmonary hypertension in patients with interstitial lung disease. Specifically this trial looks at patients who have mild pulmonary hypertension, or are in an at-risk group to developing pulmonary hypertension, in the context of their interstitial lung disease. The interstitial lung diseases addressed include idiopathic pulmonary fibrosis and non-specific interstitial pneumonitis.
MedDRA version: 9.1 Level: LLT Classification code 10064911 Term: Pulmonary arterial hypertension
Trade Name: Tracleer
Product Name: Tracleer
Pharmaceutical Form: Film-coated tablet
Pharmaceutical form of the placebo: Film-coated tablet
Route of administration of the placebo: Oral use
Royal Brompton and Harefield NHS TrustNot RecruitingFemale: yes
Male: yes
United Kingdom
212NCT00600028December 200716 December 2017Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis With ThalidomideTreatment of Chronic Cough in Idiopathic Pulmonary Fibrosis With ThalidomideIdiopathic Pulmonary Fibrosis;CoughDrug: Thalidomide;Drug: PlaceboJohns Hopkins UniversityNot recruiting50 YearsN/AAll25Phase 3United States
213NCT00625469October 200711 June 2018Pulmonary Arterial Hypertension Secondary to Idiopathic Pulmonary Fibrosis and Treatment With BosentanTreatment of Pulmonary Arterial Hypertension Secondary to Idiopathic Pulmonary Hypertension With Bosentan: A Single Center Pilot StudyPulmonary Arterial Hypertension;Idiopathic Pulmonary FibrosisDrug: bosentanRajan SaggarActelionNot recruitingN/AN/AAll0Phase 4United States
214EUCTR2007-002324-15-GB04/09/200719 March 2012The efficacy and safety of co-trimoxazole therapy in patients with idiopathic interstitial pneumonia - TIPACThe efficacy and safety of co-trimoxazole therapy in patients with idiopathic interstitial pneumonia - TIPACIdiopathic Interstitial Pneumonia
MedDRA version: 9.1 Level: LLT Classification code 10022619 Term: Interstitial pulmonary fibrosis
Trade Name: Septrin
Product Name: co-trimoxazole
Product Code: N/A
Pharmaceutical Form: Tablet
INN or Proposed INN: N/A
CAS Number: 8064902
Current Sponsor code: N/A
Other descriptive name: CO-TRIMOXAZOLE
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 480-
Pharmaceutical form of the placebo: Tablet
Route of administration of the placebo: Oral use
University of East AngliaNot RecruitingFemale: yes
Male: yes
United Kingdom
215NCT00532233September 200716 December 2017SD, IL-13 Production Rate in IPFA Open-label, Multicenter Study, With a Single Intravenous Dose of QAX576 to Determine IL-13 Production in Patients With Idiopathic Pulmonary FibrosisIdiopathic Pulmonary FibrosisDrug: QAX576Novartis PharmaceuticalsNot recruiting40 Years80 YearsAll52Phase 2United States
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
216NCT00514683August 200719 October 2017Safety And Efficacy of BIBF 1120 in Idiopathic Pulmonary FibrosisA 12 Month, Double Blind, Randomized, Placebo-controlled Trial Evaluating the Effect of BIBF 1120 Administered at Oral Doses of 50 mg qd, 50 mg Bid, 100 mg Bid and 150 mg Bid on Forced Vital Capacity Decline During One Year, in Patients With Idiopathic Pulmonary Fibrosis, With Optional Active Treatment Extension Until Last Patient Out.Pulmonary FibrosisDrug: low dose BIBF1120 once daily;Drug: low dose BIBF 1120 twice daily;Drug: intermediate dose BIBF 1120 twice daily;Drug: high dose BIBF 1120 twice daily;Drug: placeboBoehringer IngelheimNot recruiting40 YearsN/AAll432Phase 2Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;China;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Korea, Republic of;Mexico;Netherlands;Portugal;Russian Federation;South Africa;Spain;Taiwan;Turkey;United Kingdom;El Salvador
217NCT00517933August 200719 October 2017Sildenafil Trial of Exercise Performance in Idiopathic Pulmonary FibrosisSildenafil Trial of Exercise Performance in Idiopathic Pulmonary FibrosisPulmonary Fibrosis;Hypertension, PulmonaryDrug: Sildenafil Citrate;Other: PlaceboDuke UniversityNational Heart, Lung, and Blood Institute (NHLBI);PfizerNot recruiting18 YearsN/AAll180Phase 3United States
218EUCTR2004-001876-37-DE27/07/200719 March 2012BENEFIT-study: A randomized placebo controlled trial of anti-TNF-alpha chimeric monoclonal antibody ( infliximab) in idiopathic pulmonary fibrosis. - BENEFITBENEFIT-study: A randomized placebo controlled trial of anti-TNF-alpha chimeric monoclonal antibody ( infliximab) in idiopathic pulmonary fibrosis. - BENEFITIdiopathic Pulmonary Fibrosis
MedDRA version: 9.1 Level: LLT Classification code 10021240 Term: Idiopathic pulmonary fibrosis
Trade Name: Remicade
Product Name: Remicade
Pharmaceutical Form: Powder for solution for infusion
Pharmaceutical form of the placebo: Solution for infusion
Route of administration of the placebo: Intravenous use
Academic Medical CentreAuthorisedFemale: yes
Male: yes
18Germany
219EUCTR2006-002875-42-DE06/07/200711 February 2013A 12 month, double blind, randomized, placebo-controlled trial evaluating the effect of BIBF 1120 administered at oral doses of 50 mg qd, 50 mg bid, 100 mg bid and 150 mg bid on Forced Vital Capacity decline during one year, in patients with Idiopathic Pulmonary Fibrosis, with optional active treatment extension until last patient out. - Effect of orally administered BIBF 1120 on FVC decline in IPFA 12 month, double blind, randomized, placebo-controlled trial evaluating the effect of BIBF 1120 administered at oral doses of 50 mg qd, 50 mg bid, 100 mg bid and 150 mg bid on Forced Vital Capacity decline during one year, in patients with Idiopathic Pulmonary Fibrosis, with optional active treatment extension until last patient out. - Effect of orally administered BIBF 1120 on FVC decline in IPFIdiopathic pulmonary fibrosis
MedDRA version: 9.1 Level: PT Classification code 10021240 Term: Idiopathic pulmonary fibrosis
Product Name: BIBF 1120
Product Code: BIBF 1120
Pharmaceutical Form: Capsule, soft
Current Sponsor code: BIBF 1120
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 50-
Pharmaceutical form of the placebo: Capsule, soft
Route of administration of the placebo: Oral use
Boehringer IngelheimNot RecruitingFemale: yes
Male: yes
400Portugal;France;Hungary;Greece;Spain;Belgium;Ireland;Bulgaria;Netherlands;Germany;United Kingdom;Italy
220JPRN-UMIN0000159292007/05/102 April 2019Prospective observational study of Idiopathic pulmonary fibrosis with Non-small-cell lung cancer(LOGIK0603)Idiopathic pulmonary fibrosisCarboplatin/paclitaxel combination therapy
(dosage and administration)
Paclitaxel (PAC):175-200mg/m2 at day1 and carboplatin (CBDCA): AUC 5-6min.mg/mL at day1 are administered and repeated every 21 days as 1 course and the treatment is aimed for more than 3 courses.
*The study is discontinued at that point if it becomes PD.
Lung Oncology Group in Kyushu, Japan (LOGIK)Not Recruiting20years-old75years-oldMale and Female60Not selectedJapan
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
221EUCTR2006-001183-24-NL06/03/200719 March 2012Effects of bosentan on morbidity and mortality in patients with Idiopathic Pulmonary Fibrosis - a multicenter, double-blind, randomized, placebo-controlled, parallel group, event-driven, group sequential, phase III study - BUILD-3Effects of bosentan on morbidity and mortality in patients with Idiopathic Pulmonary Fibrosis - a multicenter, double-blind, randomized, placebo-controlled, parallel group, event-driven, group sequential, phase III study - BUILD-3Idiopathic Pulmonary Fibrosis (IPF)
MedDRA version: 8.1 Level: LLT Classification code 10021240 Term: Idiopathic pulmonary fibrosis
Trade Name: Tracleer
Product Name: Bosentan
Product Code: Ro 47-0203
Pharmaceutical Form: Film-coated tablet
INN or Proposed INN: BOSENTAN
CAS Number: 147536978
Current Sponsor code: Ro 47-0203
Other descriptive name: Tracleer
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 62.5-
Pharmaceutical form of the placebo: Film-coated tablet
Route of administration of the placebo: Oral use
Trade Name: Tracleer
Product Name: Bosentan
Product Code: Ro 47-0203
Pharmaceutical Form: Film-coated tablet
INN or Proposed INN: BOSENTAN
CAS Number: 147536978
Current Sponsor code: Ro 47-0203
Other descriptive name: Tracleer
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 125-
Pharmaceutical form of the placebo: Film-coated tablet
Route of administration of the placebo: Oral use
ACTELION PHARMACEUTICALS LTDNot RecruitingFemale: yes
Male: yes
600Phase 3Czech Republic;Germany;United Kingdom;Netherlands;Denmark;Belgium;France;Spain;Ireland;Italy;Austria
222NCT00391443February 200719 October 2017BUILD 3: Bosentan Use in Interstitial Lung DiseaseEffects of Bosentan on Morbidity and Mortality in Patients With Idiopathic Pulmonary Fibrosis - a Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Group Sequential, Phase III Study.Idiopathic Pulmonary FibrosisDrug: Bosentan;Drug: PlaceboActelionNot recruiting18 YearsN/AAll616Phase 3United States;Australia;Austria;Belgium;Canada;Croatia;Czech Republic;France;Germany;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;Serbia;Spain;Switzerland;United Kingdom;Denmark;Former Serbia and Montenegro;Slovakia
223NCT00625079February 200711 June 2018Pulmonary Hypertension Secondary to Idiopathic Pulmonary Fibrosis And Treatment With SildenafilRandomized Placebo-Controlled Study of Sildenafil For The Treatment of Pulmonary Hypertension Secondary to Idiopathic Pulmonary Fibrosis: A Pilot StudyPulmonary Arterial Hypertension;Idiopathic Pulmonary Fibrosis;Interstitial Lung Disease;Pulmonary HypertensionDrug: sildenafilUniversity of California, Los AngelesPfizerNot recruitingN/AN/AAll0Phase 4United States
224NCT00563212January 200715 October 2018A Pilot Study of Aerosol Interferon-gamma for Treatment of Idiopathic Pulmonary FibrosisA Pilot Study of Aerosol Interferon-gamma for Treatment of Idiopathic Pulmonary FibrosisPulmonary FibrosisDrug: aerosol interferon-gammaNew York University School of MedicineNational Center for Research Resources (NCRR);Stony Brook University;Philips RespironicsNot recruiting40 Years75 YearsAll12Phase 1United States
225EUCTR2006-001183-24-BE12/12/200619 March 2012Effects of bosentan on morbidity and mortality in patients with Idiopathic Pulmonary Fibrosis - a multicenter, double-blind, randomized, placebo-controlled, parallel group, event-driven, group sequential, phase III study - BUILD-3Effects of bosentan on morbidity and mortality in patients with Idiopathic Pulmonary Fibrosis - a multicenter, double-blind, randomized, placebo-controlled, parallel group, event-driven, group sequential, phase III study - BUILD-3Idiopathic Pulmonary Fibrosis (IPF)
MedDRA version: 8.1 Level: LLT Classification code 10021240 Term: Idiopathic pulmonary fibrosis
Trade Name: Tracleer
Product Name: Bosentan
Product Code: Ro 47-0203
Pharmaceutical Form: Film-coated tablet
INN or Proposed INN: BOSENTAN
CAS Number: 147536978
Current Sponsor code: Ro 47-0203
Other descriptive name: Tracleer
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 62.5-
Pharmaceutical form of the placebo: Film-coated tablet
Route of administration of the placebo: Oral use
Trade Name: Tracleer
Product Name: Bosentan
Product Code: Ro 47-0203
Pharmaceutical Form: Film-coated tablet
INN or Proposed INN: BOSENTAN
CAS Number: 147536978
Current Sponsor code: Ro 47-0203
Other descriptive name: Tracleer
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 125-
Pharmaceutical form of the placebo: Film-coated tablet
Route of administration of the placebo: Oral use
ACTELION PHARMACEUTICALS LTDNot RecruitingFemale: yes
Male: yes
460Phase 3Czech Republic;Germany;United Kingdom;Netherlands;Denmark;Belgium;France;Spain;Ireland;Italy;Austria
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
226EUCTR2006-002174-22-DE08/11/200619 March 2012Influence of inhaled Aviptadil on CCL18 serum concentrations in patients with pulmonary fibrosis - Inhaled Aviptadil in pulmonary fibrosisInfluence of inhaled Aviptadil on CCL18 serum concentrations in patients with pulmonary fibrosis - Inhaled Aviptadil in pulmonary fibrosisPulmonary Fibrosis categorized as UIP or NSIPProduct Name: Aviptadil, 66 microgram/mL
Pharmaceutical Form: Inhalation vapour, solution
CAS Number: 40077-57-4
Other descriptive name: Vasoactive intestinal peptide
Concentration unit: µg/ml microgram(s)/millilitre
Concentration type: equal
Concentration number: 66.6-
Pharmaceutical form of the placebo: Inhalation vapour, solution
Route of administration of the placebo: Inhalation use
Mondobiotech Laboratories AnstaltAuthorisedFemale: yes
Male: yes
Germany
227NCT00463983October 200619 February 2015Treatment of Idiopathic Pulmonary Fibrosis With Long Acting OctreotidePhase 2 Study of Long Acting Octreotide in Idiopathic Pulmonary FibrosisIdiopathic Pulmonary FibrosisDrug: octreotideInstitut National de la Santé Et de la Recherche Médicale, FranceNot recruiting40 YearsN/ABoth25Phase 1/Phase 2France
228NCT00287716July 14, 200616 December 2017Three-Arm Study of the Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary FibrosisA Randomized, Double-Blind, Placebo Controlled, Phase 3, Three-Arm Study of the Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary FibrosisIdiopathic Pulmonary FibrosisDrug: Pirfenidone;Drug: PlaceboGenentech, Inc.Not recruiting40 Years80 YearsAll435Phase 3United States
229NCT00359736July 200616 December 2017Sildenafil Study to Treat Idiopathic Pulmonary FibrosisVasodilator Therapy and Exercise Tolerance in IPF PatientsAlveolitis, Fibrosing;Fibrosis, Pulmonary;Hypertension, PulmonaryDrug: sildenafilVA Office of Research and DevelopmentNot recruiting40 Years85 YearsAll29Phase 2United States
230EUCTR2006-000252-41-GB29/06/200619 March 2012A Randomized, Double-Blind, Placebo Controlled, Phase 3 Three-Arm Study of the Safety and Efficacy of Pirfenidone in Patients with Idiopathic Pulmonary FibrosisA Randomized, Double-Blind, Placebo Controlled, Phase 3 Three-Arm Study of the Safety and Efficacy of Pirfenidone in Patients with Idiopathic Pulmonary FibrosisIdiopathic Pulmonary Fibrosis (IPF)
MedDRA version: 9.1 Level: LLT Classification code 10021240 Term: Idiopathic pulmonary fibrosis
Product Name: Pirfenidone
Pharmaceutical Form: Capsule, hard
INN or Proposed INN: Pirfenidone
CAS Number: 5317-13-8
Current Sponsor code: PIR, S-7701
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 133-
Pharmaceutical form of the placebo: Capsule, hard
Route of administration of the placebo: Oral use
Product Name: Pirfenidone
Pharmaceutical Form: Capsule, hard
INN or Proposed INN: Pirfenidone
CAS Number: 5317-13-8
Current Sponsor code: PIR, S-7701
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 267-
Pharmaceutical form of the placebo: Capsule, hard
Route of administration of the placebo: Oral use
InterMune, Inc.AuthorisedFemale: yes
Male: yes
325Phase 3United Kingdom;Italy
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
231NCT00203697April 200619 February 2015Minocycline Therapy for Lung Scarring in Patients With Idiopathic Pulmonary Fibrosis - a Pilot StudyMinocycline Treatment in Patients With Idiopathic Pulmonary Fibrosis Being Treated With Standard of Care Therapy- a Pilot StudyIdiopathic Pulmonary FibrosisDrug: minocyclineUniversity of California, Los AngelesNot recruiting20 Years79 YearsBothPhase 3United States
232NCT00287729April 200616 December 2017Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary FibrosisA Randomized, Double-Blind, Placebo Controlled, Phase 3 Study of the Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary FibrosisIdiopathic Pulmonary FibrosisDrug: Pirfenidone;Drug: PlaceboGenentech, Inc.Not recruiting40 Years80 YearsAll344Phase 3United States
233NCT00125385July 200520 April 2015Study of GC1008 in Patients With Idiopathic Pulmonary Fibrosis (IPF)Phase I, Open-Label, Multi-Center, Single-Dose, Dose-Escalating, Safety, Tolerability and Pharmacokinetic of GC1008 in Patients With Idiopathic Pulmonary FibrosisIdiopathic Pulmonary FibrosisBiological: GC1008Genzyme, a Sanofi CompanyNot recruiting18 Years79 YearsBoth25Phase 1United States;Belgium
234NCT00518310May 200519 February 2015Azathioprine and Prednisone in the Treatment of Idiopathic Pulmonary FibrosisAzathioprine and Prednisone in the Treatment of Idiopathic Pulmonary Fibrosis: a Randomized, Double-Blind, Controlled StudyIdiopathic Pulmonary FibrosisDrug: Placebo;Drug: AZAPREDThorax National InstituteSociedad Chilena de Enfermedades Respiratorias;Servicio de Salud Metropolitano Oriente, Ministerio de Salud de ChileRecruiting45 Years79 YearsBoth100N/AChile
235NCT00109681April 200519 February 2015Inhaled Iloprost in Adults With Abnormal Pulmonary Pressure and Associated With Idiopathic Pulmonary FibrosisA Randomized, Double-blind, Placebo-Controlled Phase II Study to Evaluate the Safety and Pilot Efficacy of Iloprost Inhalation Solution in Adults With Abnormal Pulmonary Arterial Pressure and Exercise Limitation Associated With Idiopathic Pulmonary Fibrosis (IPF)Pulmonary Fibrosis;Pulmonary HypertensionDrug: Iloprost Inhalation Solution (Ventavis)ActelionNot recruiting40 Years85 YearsBoth50Phase 2United States
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
236EUCTR2004-000029-31-IE28/01/200519 March 2012A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Safety and Efficacy of Interferon gamma-Ib in patients with Idiopathic Pulmonary Fibrosis The INSPIRE Trial - International Study of Survival outcomes in IPF with Interferon gamma-1b) - INSPIREA Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Safety and Efficacy of Interferon gamma-Ib in patients with Idiopathic Pulmonary Fibrosis The INSPIRE Trial - International Study of Survival outcomes in IPF with Interferon gamma-1b) - INSPIREIdiopathic Pulmonary Fibrosis (IPF)Trade Name: Immukin
Product Name: Interferon gamma-1b
Pharmaceutical Form: Solution for injection
Pharmaceutical form of the placebo: Solution for injection
Route of administration of the placebo: Subcutaneous use
InterMuneAuthorisedFemale: yes
Male: yes
600Phase 3Ireland
237EUCTR2004-001261-17-IE28/01/200519 March 2012An Open-Label Study of the Safety of Subcutaneous Recombinant Interferon gamma-1b in Patients with Idiopathic Pulmonary FibrosisAn Open-Label Study of the Safety of Subcutaneous Recombinant Interferon gamma-1b in Patients with Idiopathic Pulmonary FibrosisIdiopathic Pulmonary Fibrosis (IPF)Trade Name: Immukin
Product Name: Interferon gamma-1b
Pharmaceutical Form: Solution for injection
InterMuneAuthorisedFemale: yes
Male: yes
Ireland
238NCT00105183January 200519 October 2017EZ-2053 in the Prophylaxis of Acute Pulmonary Allograft RejectionA Double-Blind, Placebo-Controlled, Multicenter, Dose-Ranging Study of an Anti-human-T-lymphocyte Immune Globulin (EZ-2053) in the Prophylaxis of Acute Pulmonary Allograft Rejection in Adult Recipients of Primary Pulmonary Allograft(s)Chronic Obstructive Pulmonary;Idiopathic Pulmonary Fibrosis;Cystic Fibrosis;Bronchiectasis;Pulmonary Vascular DiseaseBiological: Placebo;Biological: EZ-2053;Biological: EZ-2053 5mg/kgNeovii BiotechNot recruiting18 YearsN/AAll223Phase 3United States;Australia;Austria;Canada
239NCT00352482November 20048 August 2016Sildenafil to Increase Exercise Capacity in Individuals With Idiopathic Pulmonary Fibrosis and Pulmonary HypertensionSildenafil Treatment in Patients With Idiopathic Pulmonary Fibrosis and Pulmonary Hypertension - a Pilot Cross-over StudyPulmonary Fibrosis;Hypertension, PulmonaryDrug: Sildenafil (50 mg)National Heart, Lung, and Blood Institute (NHLBI)Not recruiting19 YearsN/ABoth20Phase 2United States
240NCT00075998December 200319 February 2015The INSPIRE Trial: A Study of Interferon Gamma-1b for Idiopathic Pulmonary Fibrosis (IPF)A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Safety and Efficacy of Interferon Gamma-1b in Patients With Idiopathic Pulmonary Fibrosis (The INSPIRE Trial)Idiopathic Pulmonary Fibrosis;Lung Disease;Pulmonary FibrosisDrug: Interferon gamma-1b (Actimmune)InterMuneNot recruiting40 Years79 YearsBoth826Phase 3United States
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
241NCT00076635November 200319 February 2015An Open-Label Study of the Safety of Interferon Gamma-1b in Patients With IPFAn Open-Label Study of the Safety of Subcutaneous Recombinant Interferon Gamma-1b in Patients With Idiopathic Pulmonary FibrosisIdiopathic Pulmonary Fibrosis;Pulmonary Fibrosis;Lung DiseaseDrug: Interferon gamma-1bInterMuneNot recruitingN/AN/ABoth91Phase 3United States
242NCT00162760October 200319 February 2015Treatment of Idiopathic Pulmonary Fibrosis With ThalidomideTreatment of Idiopathic Pulmonary Fibrosis With ThalidomideIdiopathic Pulmonary Fibrosis (IPF)Drug: ThalidomideJohns Hopkins UniversityCelgene CorporationNot recruiting50 Years80 YearsBoth19Phase 2United States
243NCT00080223August 31, 200316 December 2017Safety Study of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary FibrosisAn Open-Label, Phase 2 Study of the Safety of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary FibrosisIdiopathic Pulmonary Fibrosis;Pulmonary FibrosisDrug: PirfenidoneGenentech, Inc.Not recruiting40 Years85 YearsAll83Phase 2United States
244NCT00071461August 200319 February 2015Efficacy and Safety of Oral Bosentan in Patients With Idiopathic Pulmonary FibrosisA Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Bosentan in Patients With Idiopathic Pulmonary Fibrosis, Open Label ExtensionIdiopathic Pulmonary FibrosisDrug: bosentan;Drug: PlaceboActelionNot recruiting18 YearsN/ABoth158Phase 2/Phase 3United States;Canada;France;Germany;Israel;Italy;Switzerland;United Kingdom
245NCT00063869July 200319 February 2015Study Evaluating the Safety and Efficacy of Etanercept in Patients With Idiopathic Pulmonary FibrosisA Double-blind, Parallel, Placebo-controlled, Randomized Study of the Efficacy and Safety of Etanercept in Patients With Idiopathic Pulmonary Fibrosis.Pulmonary FibrosisDrug: EtanerceptWyeth is now a wholly owned subsidiary of PfizerNot recruiting40 Years80 YearsBoth88Phase 2United States
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
246NCT00131274April 200319 February 2015Gleevec Idiopathic Pulmonary Fibrosis (IPF) StudyA Double-Blind, Placebo-Controlled, Randomized Study of the Efficacy (Gleevec Imatinib Mesylate) in Patients With Idiopathic Pulmonary FibrosisIdiopathic Pulmonary Fibrosis;Lung Disease;Pulmonary FibrosisDrug: Imatinib Mesylate (Gleevec)Daniels, Craig E., M.D.NovartisNot recruiting20 Years79 YearsBoth120Phase 2/Phase 3
247NCT00189176March 200319 February 2015Safety Study of Tetrathiomolybdate in Patients With Idiopathic Pulmonary FibrosisPhase I/II Trial of Tetrathiomolybdate (TM) in Patients With Usual Interstitial Pneumonia Refractory to Previous TherapyIdiopathic Pulmonary FibrosisDrug: TetrathiomolybdateUniversity of MichiganCoalition for Pulmonary FibrosisNot recruiting35 Years80 YearsBoth23Phase 1/Phase 2United States
248NCT00052052September 200219 February 2015An Open-Label Study of the Safety and Efficacy of Subcutaneous Recombinant Interferon-Gamma 1b (IFN-Gamma 1b) in Patients With Idiopathic Pulmonary Fibrosis (IPF)An Open-Label Study of the Safety and Efficacy of Subcutaneous Recombinant Interferon Gamma-1b in Patients With Idiopathic Pulmonary Fibrosis.Lung Disease;Pulmonary FibrosisDrug: interferon-gamma 1bInterMuneNot recruiting20 Years79 YearsBoth210Phase 2United States
249NCT00052039April 200219 February 2015A Randomized, Double-Blind, Three-Arm, Phase 3b Study Comparing the Safety and Efficacy of Interferon Gamma-1b With Azathioprine, and Azathioprine Alone in Patients With IPF Receiving PrednisoneA Randomized, Double-Blind, Three-Arm, Phase IIIb Study Comparing the Safety and Efficacy of Interferon Gamma-1b Alone, IFN-Gamma 1b With Azathioprine, and Azathioprine Alone in Patients With Idiopathic Pulmonary Fibrosis Receiving PrednisoneLung Disease;Pulmonary FibrosisDrug: interferon-gamma 1b;Drug: azathioprineInterMuneNot recruiting20 Years79 YearsBoth0Phase 3Italy
250NCT00047658November 200119 February 2015A Study of the Safety and Clinical Effects of Interferon Gamma-1b in Patients With Idiopathic Pulmonary Fibrosis (IPF)A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Biology, and Clinical Effects of Interferon Gamma-1b Administered Subcutaneously to Patients With IPF Followed by an Open-Label ExtensionIdiopathic Pulmonary FibrosisDrug: Interferon-gamma 1bInterMuneNot recruiting20 Years79 YearsBoth32Phase 2United States
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
251NCT00262405January 200114 December 2015Zileuton for the Treatment of Idiopathic Pulmonary FibrosisPhase II Trial of Zileuton Compared to Azathioprine/Prednisone for the Treatment of Idiopathic Pulmonary FibrosisIdiopathic Pulmonary FibrosisDrug: zileuton;Drug: azathioprine/prednisoneUniversity of MichiganNational Institutes of Health (NIH)Not recruiting35 Years80 YearsBoth44Phase 2United States
252NCT01442779September 200019 October 2017Clinical Trial of Low Dose Oral Interferon Alpha in Idiopathic Pulmonary FibrosisClinical Trial of Low Dose Oral Interferon Alpha in Idiopathic Pulmonary FibrosisRespiratory Tract Diseases;Lung Diseases;Lung Diseases, Interstitial;Pulmonary FibrosisDrug: Interferon alpha oral lozengeTexas Tech University Health Sciences CenterAmarillo Biosciences, Inc.Not recruiting50 YearsN/AAll18Phase 2United States
253NCT00047645April 200019 February 2015A Study of the Safety and Efficacy Interferon-Gamma 1b in Patients With Idiopathic Pulmonary Fibrosis (IPF)A Randomized, Double-Blind, Placebo-Controlled, Phase III Study of the Safety and Efficacy of Subcutaneous Recombinant Interferon-Gamma 1b in Patients With Idiopathic Pulmonary FibrosisIdiopathic Pulmonary FibrosisDrug: Interferon-gamma 1bInterMuneNot recruiting20 Years79 YearsBoth330Phase 3United States
254NCT00639496March 200016 March 2015Study of the Effects of High-dose N-acetylcysteine (NAC) in Idiopathic Pulmonary Fibrosis (IPF)Idiopathic Pulmonary Fibrosis International Group Exploring NAC I Annual Study of the Effects of High-dose N-acetylcysteine (NAC) in Idiopathic Pulmonary Fibrosis (IPF)Pulmonary FibrosisDrug: n-acetylcysteine;Drug: placeboZambon SpANot recruiting18 Years75 YearsBoth184Phase 3Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom
255NCT00074698September 199419 February 2015Safety and Tolerability Study of FG-3019 in Patients With Idiopathic Pulmonary FibrosisA Phase 1 Study of the Safety, Pharmacokinetics, and Biologic Activity of Escalating Doses of FG-3019 in Subjects With Idiopathic Pulmonary FibrosisIdiopathic Pulmonary FibrosisDrug: FG-3019FibroGenNot recruiting21 Years80 YearsBoth27Phase 1United States
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
256NCT03591926January 190015 October 2018A Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of SM04646 Inhalation Solution in Subjects With Idiopathic Pulmonary Fibrosis (IPF)A Phase 2a, 24-Week, Multi-Center, Open-Label Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of SM04646 Inhalation Solution in Subjects With Idiopathic Pulmonary Fibrosis (IPF)Idiopathic Pulmonary FibrosisDrug: SM04646Samumed LLCNot recruiting40 Years80 YearsAll0Phase 2Australia;New Zealand
257JPRN-JapicCTI-14245223 April 2019A Phase 2, Multicenter, Double-Blind Within Cohort, Dose-escalation Study to Evaluate the Safety and Tolerability of Multiple Doses of CAT-354 (Tralokinumab) in Japanese Patients With Idiopathic Pulmonary FibrosisA Phase 2, Multicenter, Double-Blind Within Cohort, Dose-escalation Study to Evaluate the Safety and Tolerability of Multiple Doses of CAT-354 (Tralokinumab) in Japanese Patients With Idiopathic Pulmonary FibrosisIdiopathic Pulmonary FibrosisIntervention name : Tralokinumab is a human recombinant monoclonal antibody (MAb) of the subclass that specifically binds human IL-13, blocking interactions with the IL-13 receptor
Dosage And administration of the intervention : Low Dose, Biological: tralokinumab cohort 1, High Dose, Biological: tralokinumab cohort 2
AstraZenecaMedImmune LLC50BOTHPhase 2

先頭へ